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Abstract 
Influenza is a one of the most important respiratory viruses, and it infects millions of 
people every year. Due to mutational changes in the virus genome (antigenic drift), 
influenza cause occasional pandemics. Pandemic influenza strains arise when gene 
segments from two or more influenza viruses re-assort (antigenic shift), leading to a 
novel virus. Vaccination is still the most effective way of preventing influenza, and 
the recent H1N1 pandemic emphasised the need for effective pandemic vaccines that 
can induce rapid protection in an immunologically naïve population. Mucosally 
administered vaccines are an attractive approach for delivery of influenza vaccines 
since they are needle-free and have the ability to induce mucosal immune responses. 
Intranasal vaccination against influenza has been used for decades, however, an 
inactivated intranasal influenza vaccine was recently associated with Bell’s Palsy 
(facial nerve paralysis). Sublingual vaccination (application under the tongue) can be 
a novel alternative for mucosal administration of influenza vaccines. 
 
Avian influenza subtypes have previously shown to be poorly immunogenic in man, 
thus an effective adjuvant is needed to boost the vaccine effect. In this study we have 
vaccinated BALB/c mice intramuscularly, intranasally or sublingually with two doses, 
three weeks apart, of a virosomal H5N1 influenza vaccine (2 µg of haemagglutinin) 
alone or in combination with 7.5 µg of the novel mucosal adjuvant c-di-GMP. Serum, 
saliva and nasal wash samples were analysed for influenza specific antibodies using 
the ELISA and haemagglutination inhibition (HI) antibodies were detected in serum 
and saliva using the HI assay. Splenocytes were used in the memory B cell ELISPOT, 
and stimulated in vitro before the cytokine profiles were measured by multiplex bead 
assay. In addition, influenza stimulated splenocytes were fixed and stained 
intracellularly for cytokines, and the frequency of cytokine producing cells was 
determined using multiparametric flow cytometry.  
 
The intramuscular, the intranasal and the sublingual routes all induced strong immune 
responses both in the humoral and the cellular immune assays when the virosomes 
were combined with c-di-GMP adjuvant. The non-adjuvanted vaccine induced lower 
immune responses as compared to the adjuvanted vaccine, irrespective of 
administration route. After the first vaccine dose, intramuscular administration of the 
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adjuvanted vaccine showed the highest IgG antibody response. In contrast, after the 
second vaccine dose, the intranasal adjuvanted group showed the highest responses in 
all assays. A strong local humoral immune response together with systemic IgG and 
IgA antibodies was elicited in both the sublingual and the intranasal adjuvanted 
groups. Interestingly, the intranasal adjuvanted group showed a dominant Th1 profile, 
whereas the sublingual adjuvanted group showed a more balanced Th2/Th1 profile. In 
addition, high levels of IL-17 (a Th17 cytokine) were produced in both the mucosal 
administered vaccines groups. The frequency of multifunctional CD4+ T cells was 
highest in the intranasal adjuvanted group, but also sublingual vaccination of 
virosomes combined with c-di-GMP induced high frequencies of multifunctional T 
cells.  
 
This is the first study to report that sublingual vaccination with H5N1 virosomes 
induces both humoral and cellular immune responses. These results demonstrate that 
the sublingual route is a promising way of administering influenza vaccines; we 
therefore suggest further investigation of influenza vaccines administered 
sublingually.  
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1 Introduction 
 
1.1 The Influenza virus 
Influenza virus is a major respiratory virus in humans. The virus causes annual 
outbreaks, normally during late autumn or early winter in the temperate climate zones 
of the northern and southern hemispheres. The influenza virus is spreads by aerosols 
from coughing and sneezing, and every year the World Health Organisation (WHO) 
estimates that 20 % of children and 5 % of adults worldwide are infected. Each year, 
influenza causes excess mortality, hospitalisation and absenteeism and therefore has a 
huge social and economical impact on society. Influenza can also cause pandemics at 
unpredictable intervals, and previous influenza pandemics have caused millions of 
deaths worldwide [1].  
 
1.1.1 Taxonomy, Structure and Nomenclature 
The influenza virus is a member of the Orthomyxoviridae family. It is an enveloped 
virus with either spherical or filamentous (pleomorphic) morphology with a diameter 
of 80-120 nm. There are three different types of influenza virus: A, B and C. The 
three influenza types have antigenic differences in the structural proteins matrix 
protein (M) and nucleoprotein (NP) (figure 1.1). The genome of influenza A and B 
have eight negative stranded RNA segments. Type A and B viruses commonly cause 
human disease, whereas influenza C causes a mild illness. Influenza A can be further 
subdivided according to structural differences in the surface glycoproteins; 
haemagglutinin (HA) and neuraminidase (NA) of which 9 subtypes of NA and 16 
subtypes of HA have been identified [2, 3]. HA is the most abundant surface 
glycoprotein on the influenza virus, and has several functions. Firstly, it is responsible 
for the attachment of the virus to the host cell, via binding to sialic acid on the surface 
of epithelial cells. Secondly, it promotes fusion between the viral envelope and the 
host cell and third, as the name suggests, the protein haemagglutinates red blood cells. 
All these functions make HA one of the most important determinants of viral 
pathogenicity [4, 5]. HA is activated by cleavage of the protein into two subunits 
(HA1 and HA2) that are held together by a disulphide bond. Most antibodies to HA 
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neutralize the virus and there are 5 antigenic sites on the globular head [6]. The other 
surface glycoprotein is NA, which is responsible for cleavage of sialic acid on 
glycoproteins. This promotes infection by mediating release of newly formed 
influenza virons from the host cell. NA may also play an important role in the 
initiation of infection, by removing decoy receptors in the airway epithelium [7].  
 
A standardised nomenclature for influenza viruses includes the following: type (A, B 
or C), the species it was first isolated from (if non human), place of original isolation, 
isolation number, and surface antigen (HA and NA). An example is 
A/Vietnam/1194/2004 (H5N1), which is a strain of influenza type A, H5N1, isolated 
from man in Vietnam in 2004 [8]. 
 
 
Figure 1.1: Schematic illustration of the influenza virion 
The surface antigens haemagglutinin (HA) and neuraminidase (NA) radiate from the viral 
envelope. M2 is embedded in, whereas M1 lines, the viral envelope. The eight gene- 
segments code for different viral proteins and are encompassed by nucleoproteins (NP) and 
have the polymerase complex (PA, PB1 and PB2) attached. From reference [9]. 
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1.1.2 Replication cycle 
Briefly, the replication cycle of influenza virus starts with the binding of HA to sialic 
acid on the glycoproteins of the host epithelial cells (figure 1.2). After binding the 
virus is endocytosed by the host cell. The acidic environment in the endosome leads 
to a conformational change in the HA, which exposes the hydrophobic region of HA2 
and promotes fusion of the viral and endosomal membranes. The M2 proteins form a 
proton channel, thus facilitating influx of protons into the endosome and further 
acidification of the viral envelope, resulting in final viral uncoating. The nucleocapsid 
is released into the cytosol, and transported into the nucleus of the host cell. Here, 
viral RNA is transcribed into viral mRNA and positive-stranded RNA that serve as 
templates for new viral negative-stranded RNA segments. Since influenza is a 
negative stranded RNA virus, it carries its own RNA-dependent RNA polymerase 
(comprising of PA, PB1, PB2 and NP). But the enzyme lacks the ability to cap and 
methylate the mRNA, so it steals the 5’ cap region from host mRNA, using it as a 
primer for viral mRNA, allowing it to bind to the ribosome. After transcription viral 
mRNA enters the cytosol where it is translated into viral proteins. The surface 
glycoproteins (HA and NA) and M2-protein are further processed in the endoplasmic 
reticulum and in the golgi apparatus, and transported to the cell surface after 
processing. The newly replicated genomic segments associate with the polymerase 
and the NP protein in the nucleus, forming nucleocapsids. The nucleocapsids are 
transported to the cytoplasm with help from the NS2 protein, and assemble with 
surface proteins and matrix proteins before budding and release of new virus, 
approximately 8 hours after infection [10]. 
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Figure 1.2: Replication cycle of influenza virus 
Replication starts with binding of the virus to the host cell. The virion is further uncoated, and 
the viral RNA is released and transported to the nucleus where synthesis of viral mRNA and 
replication of RNA is carried out. Viral mRNA is translated into viral proteins and the newly 
synthesised viral particles assemble and bud from the host cell. See text for more details. 
From reference [11].  
 
 
1.2 Epidemiology 
1.2.1 Antigenic Drift and Shift 
The influenza virus undergoes constant antigenic genetic change, namely antigenic 
drift and antigenic shift. These are mechanisms to avoid the host’s immunity. 
Antigenic drift is point mutations in the gene segments, due to the high error rate of 
the RNA-dependent RNA polymerase and the lack of proof reading. The mutations 
can cause changes throughout the virus genome, but the most important antigenic 
changes occur in the surface glycoproteins (HA and NA). This result in pre-existing 
antibodies in a vaccinated or previously infected subject only partially recognising the 
antigenically changed HA and NA. The antibodies are therefore prevented from 
eliciting their neutralizing activity and host immunity is wane. Antigenic drift is the 
cause of for annual influenza epidemics and results in the need for annual vaccination.  
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Antigenic shift is a reassortment of gene segments, which can cause major changes in 
the influenza A virus. This can happen when a host (e.g. a pig) is infected with two or 
more different subtypes of influenza A. Antigenic shifts are not produced by influenza 
B viruses because they have only one subtype of HA and NA and predominantly 
infect humans. These antigenic shifts can lead to novel viruses that are able infect 
humans, and can lead to influenza pandemics, because the human population is 
immunologically naïve to the new virus (reviewed in [12]).  
 
During the 20th century three influenza pandemics occurred, in 1918, 1957 and 1968. 
The “Spanish flu” in 1918 caused up to 50 million deaths worldwide. This pandemic 
was caused by an H1N1 virus [13], which was highly virulent due to extensive 
replication in the lungs [14] followed by high incidence of viral pneumonia. These 
two virulent features were mainly caused by the HA (causing specific receptor 
binding in the lungs) and the polymerase complex (reviewed in [15]). Another 
characteristic of the virus was that it mainly caused illness and deaths in young adults 
[16]. In 1957 a novel H2N2 virus caused a pandemic called the Asian influenza and 
replaced the H1N1 virus. Only eleven years later, in 1968, a new shift in influenza A, 
H3N2, occurred in Hong Kong and thereby called the Hong Kong influenza pandemic 
[1]. Together the Asian influenza and the Hong Kong influenza caused approximately 
2 million deaths. In 1977, the H1N1 virus reappeared in Russia, however, it was 
restricted to persons under the age of 25 [1] and thus not defined as a pandemic. The 
last pandemic occurred in 2009 and was caused by an influenza A H1N1 virus of 
swine origin, also called “Swine flu”. The virus was first discovered in Mexico, but 
rapidly spread throughout the world and approximately 200 million people were 
infected worldwide [17]. Luckily, the pandemic strain generally caused a mild and 
self-limiting disease, and the average case fatality rate was at 0.15 – 0.25 %. 
Nonetheless the high incidence of deaths in young people compared to other age 
groups, did pose a reason for alertness [17].  
 
Another influenza subtype has caused great concerns, namely the highly pathogenic 
avian influenza A H5N1 virus. This influenza subtype primarily affects birds, but 
sporadic transmission to other species (e.g. man or swine) has occurred. The first case 
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of influenza A H5N1 in humans was reported in Hong Kong in 1997 [18]. This virus 
infected 18 people of who 6 died. However, the virus was eradicated by mass culling 
of all the poultry in Hong Kong. In 2003, the virus reappeared causing zoonosis and 
has continued to infect man. The average mortality rate since 2003 has been 60%, and 
the highest mortality rates have been reported in young people [19]. The different H5 
viruses that have evolved from A/goose/Guandong/96 (H5N1), can be designated into 
clades based on a phylogenetic characterisation and sequence homology of the HA 
gene. The WHO defined 10 clades (0-9) of the H5N1 virus in 2008, and as the virus 
continues to evolve different sub-clades arise [20]. To date, there has not been 
efficient transmission of H5N1 between humans [21], but if the H5N1 virus 
undergoes antigenic shift with a human influenza virus or adapts its receptor affinity 
to allow upper respiratory tract infections, a future H5N1 pandemic virus can be a 
fact. Considerable research aims at finding the best H5N1 vaccine to prepare for this 
potential future pandemic. 
 
 
1.2.3 Tropism and Ecology 
The natural reservoir for influenza A viruses is aquatic birds, where one can find all 
types of HA and NA [2, 3, 22]. Influenza virus can be transmitted from aquatic birds 
to other species like humans, pigs, dogs, horses and ferrets, but only a limited 
numbers of subtypes have established themselves in the different species. The strains 
circulating in humans have surface molecules from HA (H1, H2 and H3) and NA (N1 
and N2), but also avian H5, H7 and H9 viruses have caused zoonosis in man. In pigs, 
viruses containing HA (H1, H2, H3) and NA (N1 and N2) have been isolated 
although the H1N1 and H3N2 are the most frequently circulating subtypes (reviewed 
in [2]).  
 
The different influenza virus subtypes have adapted to different species. HA is the 
main determinant of tissue tropism, and thereby the infectivity, pathogenicity and 
virulence [4]. HA binds to sialic acid, and the type of glyco-conjugation of the sialic 
acid in the tissue can determine what type(s) of viruses that can infect a specific tissue 
and/or species (tropism). The HA of avian and equine influenza viruses bind to 
α(2,3)-linked sialic acid receptors, whilst the HA in most human influenza viruses 
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bind to α(2,6)-linked sialic acid receptors [23]. The reason avian influenza less 
efficiently infects and spreads in humans can be due to the HA binding specificity and 
may also increase the severity of avian influenza disease in humans. Influenza virus 
subtypes normally circulating in humans most often cause uncomplicated infection of 
the upper respiratory tract, where α(2,6)-linked sialic acid receptors are predominant. 
In contrast, the lower respiratory tract has mainly α(2,3)-linked sialic acid receptors, 
and avian influenza therefore has a tendency to cause lower respiratory tract 
infections in man. Pigs have both types of α(2,6) and α(2,3) containing cells in their 
trachea. Consequently, both types of viruses can infect this species [24], and pigs can 
thus work as a mixing vessel for new influenza strains. 
 
An important determinant of influenza virulence is the cleavage of HA into HA1 and 
HA2 [25]. The virus is dependent upon host proteases to cleave the HA, allowing 
fusion of virus with the host cell membrane. In some highly pathogenic avian 
influenza viruses (HPAIV) the HA has a polybasic cleavage site. HA can therefore be 
cleaved by a number of proteases in different tissues and the viruses’ ability to infect 
other types of tissues increases, resulting in systemic spread.  
 
1.2.4 Clinical manifestation 
The average incubation time for influenza is 2 days, but can vary from 1-4 days. After 
the infection the virus can cause asymptomatic to severe illness and ultimately death. 
The elderly, people with chronic heart, metabolic and respiratory diseases and 
immune deficiencies are more prone to severe illness. The symptoms of influenza are 
usually fever, fatigue, sore throat, runny nose, cough and myalgia (muscle pain). 
Cardiac involvement, neurological syndromes and secondary infections such as 
bacterial pneumonia and myostitis can be complications of influenza, but are rare in 
healthy adults. Primary viral pneumonia can also occur. An acute influenza infection 
in young children is often more serious than in adults, because young children have 
less experience of influenza, and the infection is often accompanied by higher fever, 
gastrointestinal symptoms, otitis media, myostitis and croup [10].  
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1.3 The Immune Response to Influenza 
The immune system is divided into the innate immune system and the adaptive 
(acquired) immune system. In the first line of defence against foreign antigens, we 
find the innate immunity comprising of immediate recognition of pathogen patterns 
based on general specificity, whilst the adaptive immune system requires longer time 
to be activated, but it is more specific and is characterised by immunological memory. 
Both the innate and the adaptive immune systems are acting closely together in the 
prevention and eradication of influenza virus from the body.  
 
1.3.1 The Innate Immune System 
Innate immunity is acting early in the response to microbial agents like viruses and 
bacteria. It includes the physical and chemical barriers of the body, like the skin and 
the mucosal surfaces, phagocytes, natural killer cells (NK-cells) and circulating 
plasma proteins. In addition, the innate immune system produces inflammatory 
cytokines that initiates several defence mechanisms including recruitment of 
neutrophils, macrophages and lymphocytes to the infected site, and cytokine 
production that helps activate the adaptive immune system.  
 
The innate immune system recognises microbes via pathogen-associated molecular 
patterns (PAMPs) that bind to pattern recognition receptors (PRRs). The specificity 
and diversity of these receptors is limited and they include Toll-like receptors (TLR), 
C-type lectin receptors, scavenger receptors, Nod-like receptors and N-formyl Met-
Leu-Phe receptors among others. All these receptors are found on phagocytic cells 
(macrophages, neutrophils and dendritic cells (DCs)), either on the plasma membrane 
or in the cytoplasm. In addition, TLRs are also mainly found on endothelial cells. The 
internal TLRs 3 and 7 are important for recognising viral genomic material from e.g. 
influenza virus [26]. After a microbe has been recognized by a PRR, the effector cells 
of the innate immune system can either phagocytose the microbe or kill the infected 
cell. Neutrophils and macrophages are phagocytes that can engulf and digest microbes 
by phagocytosis whereas NK-cells, which are derived from the common lymphoid 
progenitor cells, can recognise stressed and infected cells and initiate killing of these 
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cells. NK-cells are therefore very important in the initial defence against intracellular 
microbes, such as viruses.  
 
Circulating plasma proteins can also recognise PAMPs. These proteins include 
complement, pentraxin and collectin. Pentraxin and collectin work by opsonisation of 
microbes and activation of the complement system (via the classical pathway and 
lectin pathway respectively). The complement system works by opsonising microbes, 
killing microbes by lysis and activating leukocytes by inflammatory mediators. 
Complement proteins have been shown to contribute in the protection against 
influenza [27].  
 
Pro-inflammatory cytokines (e.g. TNF-α, IFN-γ and IL-1) and chemokines are an 
important part of the innate immune system, and helps to activate the adaptive 
immune system. Type I interferons (IFN-α and IFN-β) are also important cytokines in 
the innate immune response, and provides a powerful defence against influenza virus 
by creating a cellular antiviral state, preventing new cells from being infected [28]. In 
addition, type I interferons work as potent stimulators of the adaptive immune system 
[29, 30]. 
 
1.3.2 The Adaptive Immune System 
Five to ten days after primary infection, the adaptive immune system is fully activated 
[31]. The activation is highly dependant on help from innate immune responses, 
especially cytokine help and antigen presentation by DCs. The adaptive immune 
system has two arms: the humoral and the cellular arms, represented by B-cells and 
antibodies, and T-cells respectively. The two arms are closely connected and 
dependent on each other.  
1.3.2.1 Cellular Immunity 
T-lymphocytes are the effector-cells of cellular immunity. T-lymphocytes can be 
divided into CD4+ and CD8+ T cells by the distinct surface molecules, also called 
helper T-lymphocytes and cytotoxic T-lymphocytes (CTL) by their main mode of 
action after activation. 
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Both CD4+ and CD8+ T cells develop from the same precursor, the common lymphoid 
progenitor cell. The main the development of T cells occurs in the thymus without 
exposure to foreign antigens. The mature T cell migrates to the peripheral lymphoid 
organs, where it scans professional antigen presenting cells (APCs) for a peptide with 
affinity for its specific T-cell receptor (TCR). The activation that occurs when the 
immunological synapsis containing major histocompatibility complex (MHC) and 
TCR complex forms, may stimulate the lymphocyte to proliferate and further 
differentiate.  
 
CD4+ T cells have CD4 co-receptors that bind to MHC class II molecules. MHC class 
II are mainly found on professional APCs and bind peptides processed in endosomes, 
i.e. extracellular proteins endocytosed by the APC. The activation and maturation of 
APCs (e.g. increased expression of MHC class II and co-stimulatory molecules) are 
stimulated by innate immune signalling (via TLRs or other innate immune receptors). 
The most important APCs are DCs, macrophages and B-cells. When a CD4+ T cell 
meet an APC with an MHC class II peptide complex which it has affinity for, the T 
cell is activated and can undergo clonal expansion and differentiation into an effector 
cell and/or memory cell. In order to activate naïve CD4+ T cells, signals are required 
from co-stimulatory molecules B7-1/CD80 and B7-2/CD86 (mainly found on 
activated DCs) and cytokines (IL-12 or IL-4) in addition to the signals the TCR 
complex generate. The CD4+ T cells then start to produce large amounts of IL-2, a 
cytokine working as a growth factor for T cells in an autocrine and/or paracrine 
manner.  
 
CD4+ T cells can differentiate into at least four different subsets; Th1, Th2, Th17 and 
Treg. The different subsets vary in what types of cytokines they secrete, and therefore 
in effector functions. Tregs are regulatory T cells, which are important in the 
suppression of other T cells (mainly via IL-10, IL-35 and TGF-β) and thereby 
induction of immunological tolerance (reviewed in [32]). After an infection with 
microbes that activate macrophages and NK-cells, production of IL-12 and IFN-γ is 
induced, which subsequently promote differentiation of CD4+ T cells into Th1 cells. 
Th1 cells predominantly produce IFN-γ, IL-2 and TNF-α. TNF-α and IFN-γ are pro-
inflammatory cytokines inducing macrophage activation and promoting phagocytosis 
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of microbes. In mice, Th1 cytokines stimulate IgG2a antibody class-switch. The Th2 
subset is encouraged by helminthic infections and allergens, which induce production 
of IL-4 from mast cells or DCs. Th2 cells mainly produce IL-4, IL-5, IL-10 and IL-13 
[33], and induce differentiation of B-cells into plasma cells and the subsequent 
production of antibodies. Th2 especially stimulates the production of IgE, IgM, IgA 
and IgG1 antibodies. Both Th1 and Th2 boost their own subsets (by autocrine 
signalling) and regulate the other subset by the production of inhibitory cytokines 
[34]. The third main subset of CD4+ T cells is Th17. These cells produce IL-17, 
which can stimulate neutrophils and induce phagocytosis of extracellular pathogens. 
The Th17 subset has also shown to induce inflammation and autoimmunity [31].   
 
Some CD4+ T cells have the ability to produce more than one cytokine 
simultaneously, and are hence called multifunctional T cells. T cells producing three 
cytokines (triple producers) have also been shown to produce more of each cytokine 
per cell as compared to single cytokine producing T cells [35]. It has been 
demonstrated that these multifunctional Th cells can be a good correlate for vaccine 
protection in vaccination against Leischmania major [36], and it is speculated if 
multifunctional Th cells also are important in the protective effect of influenza 
vaccines [35].  
 
CD8+ T cells recognise MHC class I peptide complexes by its TCR, and differentiate 
into CTLs after the appropriate stimulation with co-receptors and cytokines (e.g. IL-
2). MHC class I is present on the surface of all nucleated cells in the body (with a few 
exceptions), and present intracellular peptides. After a CTL has become activated, the 
target cell (e.g. a virus infected cell) is killed by either granzyme/perforin complexes 
or Fas/FasL interactions, which both induce apoptosis. CTLs are therefore central in 
the defence against intracellular pathogens such as viruses. 
 
 
1.3.2.2 Humoral Immunity 
B-lymphocytes and antibodies (immunoglobulin, Ig) (figure 1.3) are the main features 
of humoral immunity. B-lymphocytes recognize extracellular microbes (antigens) and 
can differentiate into plasma cells, which secrete antibodies (antibody secreting cells 
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(ASC)). Antibodies can bind to and neutralise microbes as well as activate 
macrophages and complement.  
 
B-lymphocytes develop from the same precursor as all blood cells, the pluripotent 
haematopoietic stem cell. B cells develop in the bone marrow, and enter the spleen 
and other secondary lymphoid tissues via the blood as immature B cells. Here they 
mature before re-circulating between the blood and the secondary lymphoid organs 
until the naïve B cells encounter a specific antigen. If T cell help by an activated Th 
cell to cognate antigen is provided, antigen-specific B cells will differentiate into 
short-lived IgM-producing plasma cells while others will form germinal centres 
where they proliferate and undergo affinity maturation and class-switch. Affinity 
maturation is a process where the Ig V (variable) genes undergo somatic 
hypermutation, and the B cells with high-affinity Ig survive the selection, before 
differentiation into a memory B cell or into a plasma cell.  
 
 
Figure 1.3: Antibody structure 
Antibodies consist of two heavy chains and two light chains joined together by disulfide 
bridges (not shown). Each heavy and light chain has variable and constant regions, and the 
antigen binds to highly diverse parts of the variable regions. Modified from reference [37]. 
 
Naïve B cells express IgM and IgD receptors on their surface. The first time a naïve B 
cell encounter an antigen (either by infection or vaccination), IgM is the first antibody 
secreted followed by a weak IgG response (primary response). IgM is secreted as a 
pentamer and mainly function as a complement activator. The subsequent exposure of 
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the same antigen, the memory B cells is rapidly activated and the antibody response 
becomes faster and stronger than the first response (secondary response) (figure 1.4).   
 
The change from one antibody class to another (e.g. IgM to IgG) occurs when B cells 
undergo class-switch. Class-switch is irreversible because the gene rearrangement is 
done by deletion. IgG antibodies dominates the secondary response, and is secreted as 
a monomer. In mice, four different subclasses of IgG can be secreted (IgG1, IgG2a, 
IgG2b and IgG3). Which IgG subclass produced, is largely dependent on the Th 
polarisation (either Th1 or the Th2 skewed response, as discussed above). IgG can 
opsonise bacteria and virus in the extracellular fluid, activate complement and 
mediate antibody-dependent cell-mediated cytotoxicity (ADCC). Other antibody 
classes are IgA (an essential part of mucosal immunity, described below) and IgE. IgE 
is important for the defence against helminths and is also partly responsible for 
allergic reactions (immediate hypersensitivity).  
 
 
Figure 1.4: Primary and secondary antibody immune response 
Primary vaccination/infection is characterised by an initial IgM response, which may during 
the course of events develop into a weak IgG response. The secondary response (or booster 
dose) is much more rapid and is dominated by IgG antibodies. Modified from reference [38]. 
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1.3.2.3 Mucosal immunity 
The entry site for influenza virus is the mucosal epithelium in the nose and upper 
respiratory tract. The mucosal sites in the body have associated specialised lymphoid 
tissue; the mucosal immune system (figure 1.5). This comprises of mucosal associated 
lymphoid tissues (MALT), which in the nose are called nasal associated lymphoid 
tissues (NALT).  
 
 
Figure 1.5: Mucosal immunity 
Details are described in the text. From reference [39]. 
 
Microfold cells (M-cells) can be found in between the mucosal epithelial cells. These 
cells are in close contact with sub-epithelial lymphocytes and DCs. Antigens that 
come in contact with the mucosal surface are transcytosed by M-cells and taken up by 
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DCs at the basolateral side of the epithelium. The DCs are transported to the draining 
lymph node where they activate CD4+ T cells, which subsequently get the ability to 
activate B-cells (as previously described). The DCs found in MALT have a special 
ability to induce CD4+ T cells to produce transforming growth factor β (TGF-β) and 
IL-10, stimulating IgA class-switch in B-cells [40, 41]. Large amounts of IgA are 
secreted by plasma cells as dimers and/or polymers, joined together by a J-chain. 
Before transportation to the lumen, the IgA dimmer/polymer is bound to a polymeric 
Ig receptor (pIgR). The IgA-pIgR complex is transported across the epithelial cell, 
and by proteolytic cleavage the SIgA is released. The secretory component (SC) is the 
secreted part of pIgR, which is covalently bound to SIgA. This binding makes SIgA 
more stable than other antibodies [41]. On the epithelial surface it can bind to and 
neutralise pathogens and toxins, preventing them from entering the host [31, 42]. 
 
 
1.4 Prophylaxis and Treatment 
Symptomatic treatment with analgesics, anti-pyretics, cough relief and anti-
congestive drugs are the most effective way of dealing with the influenza. Antiviral 
drugs (e.g. Tamiflu and Relenza) can also be used to treat influenza, but are only 
efficient if used the first 48 hours after the symptoms has presented. Prevention of 
influenza disease by vaccination is therefore the most important way to minimize the 
impact of influenza.  
 
1.4.1 Antiviral drugs 
Antiviral drugs can be used as prophylaxis and treatment for influenza virus. There 
are two classes of anti-influenza antiviral drugs, neuraminidase inhibitors (NAI) and 
M2 ion channel blockers. A recent Cochrane Review showed that NAIs have high 
effectiveness against influenza when given prophylaxically or post-exposure, but 
when given as treatment of influenza symptoms the effectiveness was much lower 
[43]. Resistance towards influenza antiviral drugs due to mutations in the influenza 
virus is a growing problem, thus widespread use in healthy adults during seasonal 
influenza is not recommended. In a future pandemic with novel influenza virus, 
antiviral drugs will be an important part of the treatment [43]. 
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There are two NAIs on the market in Norway, oseltamivir (Tamiflu™) and zanamivir 
(Relenza™). A novel NAI in, named peramivir, is currently in clinical trials for 
intravenous administration [44], however an Emergency Use Approval was issued by 
the U.S. Food and Drug Administration during the H1N1 pandemic in 2009 [45]. The 
NAIs are active against both Influenza A and B viruses, and they are indicated for use 
in the first 48 hours of influenza symptoms and prophylactically after exposure to 
clinical influenza [46]. They work by inhibiting the enzyme function of NA, thus 
preventing the influenza virus infection and replication [47]. Several resistance 
mutations have been described against oseltamivir in both seasonal H1N1 [48] and 
H5N1 viruses [49]. Resistance to zanamivir has also been reported, but is very rare 
[50].  
 
Another type of antiviral treatment against influenza is the M2 channel blockers, 
which inhibits acidification of the virion and prevents uncoating of the virus. These 
drugs are not much in use because of resistance problems [51].  
 
 
1.4.2 Influenza Vaccines 
Seasonal vaccination is most important in the elderly (people older than 65 years), 
children and individuals with chronic conditions [52]. In 2003, nearly 300 million 
seasonal vaccines were manufactured, and the number is increasing every year [53]. 
In recent years, the fear of an influenza H5N1 pandemic placed pandemic influenza 
vaccines in the spotlight. A considerable effort has been put into development of 
pandemic vaccines, which allowed an effective pH1N1 to be rapidly manufactured 
and deployed. Over 350 million pH1N1 vaccine doses were administered globally 
during the 2009 pandemic [54].  
 
The influenza virus is continuously changing every year due to antigenic drift. The 
WHO created a global surveillance system, called Global Influenza Surveillance 
Network (GISN), to collect global antigenic and genetic data for biannual influenza 
vaccine composition to be decided [55]. GISN consists of National Influenza Centres 
that collects samples from patients with influenza like symptoms and WHO 
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Collaborating Centres who analyse the samples to decide whether a previously 
circulating strain or a new strain should be incorporated into the annual vaccine [56]. 
A lot of research has also focused on the development of pre-pandemic vaccines and 
so far five pre-pandemic H5N1 vaccines have been licensed (reviewed in [57]). 
 
1.4.2.1 Evaluation of Influenza Vaccines 
The Committee for Medicinal Products for Human Use (CHMP) provided a note on 
requirements for influenza vaccines, to standardize the criteria for production, and for 
evaluating tolerance and immunogenicity, of seasonal influenza vaccines [58]. As a 
standard, evaluation of influenza vaccines sera should be collected prior to 
vaccination and 3 weeks post vaccination. In the sera, functional antibodies against 
the vaccine strain must be detected by haemagglutination inhibition assay (HI assay) 
and/or single radial haemolysis (SRH) (the latter not discussed here). For the HI-
assay, seroconversion is described as negative pre-vaccination serum and a post-
vaccination serum antibody titre ≥40 or as a fourfold increase in post vaccination 
antibody titre (considered significant). Seroprotective titres are defined as anti-
haemagglutinin antibodies ≥40; which is regarded as a surrogate correlate of 
protection for seasonal influenza [58]. It is uncertain if this correlate applies to 
pandemic influenza vaccines [59], however, in the absence of other surrogate 
correlates of protection, serum HI titres ≥40 are also used to evaluate pandemic 
influenza vaccines [59]. In addition other immunological methods can be used to 
evaluate the immunogenicity of pandemic vaccines including measurement of 
neutralising antibodies, antibody kinetics and cell-mediated immunity [59]. 
 
1.4.2.2 Safety 
During the last 50 years, hundreds millions of doses of influenza vaccines have been 
administered worldwide. The manufacturing requirements and the accepted level of 
adverse drug reactions (ADR) for influenza vaccines in Europe are set by the 
European Medicines Agency [59]. The most common ARD after intramuscular 
influenza vaccination are mild local reactions such as pain and redness at the injection 
site and systemic flu-like symptoms [60]. But also more serious ADR like 
anaphylactic shock and GuillaIN-Barrés syndrome (a peripheral nerve system 
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disorder) have been reported at very low frequencies (reviewed in [61]). The 
incidence of these ARDs must be assessed alongside the immunogenicity in clinical 
trials prior to licensing and in a phase IV study post licensing (pharmacovigilance).  
 
1.4.2.3 Propagation of Influenza Virus 
The majority of influenza vaccines are produced in embryonated hens’ eggs. The 
virus replicates in the allantoic cavity, and the allantonic fluid  is harvested. Next, the 
virus is purified and inactivated by formaldehyde or β-propiolactone [62, 63]. To get 
maximal virus yield, a “high-growth” influenza A virus strain is used as a donor 
strain. This strain is called PR8 (A/Puerto Rico/8/34) and has been used since the 
1970s to create reassortant influenza A viruses that grow well in eggs [63]. A problem 
with propagating H5N1 virus in eggs is that the virus is highly virulent and kills the 
embryo. Reverse-genetics technology has made it possible to overcome this problem 
by removing the poly-basic cleavage site of HA associated with virulence [64]. There 
are a number of issues with the use of embryonated hens’ eggs, i.e. egg allergy, 
possible bacterial contamination leading to delay in vaccine supply and the initial 
problem of growing H5N1 in eggs. Therefore, alternative ways of producing virus for 
influenza vaccines are currently under investigation. An attractive alternative to eggs 
is to grow virus in cell cultures, and different types of continuous cell lines have been 
used to produce influenza virus that are used in licensed vaccines (reviewed in [65] 
and [66]). Influenza subunit antigens grown in plant-cells are another approach that is 
under current investigation, which avoids the need to propagate live viruses [67].  
 
1.4.2.4 Live Attenuated Influenza Vaccines 
Live attenuated vaccines are developed by growing viruses in cell culture for repeated 
passages and at low temperatures, in this way making the virus cold adapted (CA), 
reducing the virus’ ability to replicate at the temperature of the lower respiratory tract 
(37°C). Live attenuated influenza vaccines (LAIV) is registered in the USA and 
Europe as intranasal vaccines, called FluMist® and Fluenz®, respectively, which 
both are seasonal trivalent vaccines [68, 69]. The virus replication is restricted to the 
nasal cavity where the temperature is lower compared to the rest of the body. One 
dose of a trivalent seasonal LAIV has proved sufficient for protection against clinical 
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infection [70], and has been found more effective in preventing influenza infections 
than a trivalent inactivated seasonal influenza vaccine (administered intramuscularly) 
[71]. There are however, some limitations with the LAIV. It is only is approved for 
use by non-pregnant persons in the age group 2-59 years [72], should not be used by 
immunocompromised persons and viral shedding can occur after administration [73]. 
FluMist® must be kept frozen at -18°C [72], which could lead to difficulties with 
distributing the vaccine in developing countries. When it comes to pandemic LAIV 
both successful animal studies and phase I clinical trials have been conducted [72], 
but H5N1 CA reassortant showed the lowest immunogenicity of all LAIV that have 
been manufactured [74].  
 
1.4.2.5 Inactivated Influenza Vaccines 
There are different types of inactivated influenza vaccines; whole virus, split 
(chemically disrupted), subunit (isolated surface antigens) and virosomal vaccines 
(figure 1.6). Virosomes are discussed in section 1.4.1.6. Whole virus vaccines are 
more immunogenic than the split and subunit vaccines, but they can give undesirable 
ADRs because of the higher reactogenicity [75]. Whole virus vaccines are prepared 
by inactivation with formaldehyde or β-propiolactone of purified virus. Split virus 
vaccines (also called subvirion vaccines) are prepared by adding a detergent (e.g. 
deoxycholate or Triton X-100) to the whole inactivated virus, resulting in disruption 
of the lipid membrane, followed by further purification. Split vaccines show lower 
reactogenicity and fewer side effects as compared to whole virus vaccines. The split 
virus vaccine is more immunogenic than subunit, but less immunogenic than whole 
virus vaccine. The subunit formulation contains only the purified viral surface 
antigens HA and/or NA [63]. This formulation elicits fewer ADRs, but often shows 
lower immunogenicity than the other formulations and an adjuvant is therefore often 
required to elicit a sufficient immune response (adjuvants are described below) [76]. 
In addition to the inactivated vaccines, viral vector vaccines and DNA vaccines are 
under current investigation as novel ways of delivering influenza vaccines [77]. 
 
 
 
1. Introduction 
 
 30 
 
 
 
Figure 1.6: Inactivated influenza vaccines  
The whole virus vaccine is inactivated by formaldehyde or β-propiolactone and it shows great 
immunogenicity, eliciting both humoral and cellular immune response. The split virus 
vaccine contains most of the components of the whole virus, but the lipid membrane is 
chemically disrupted. Subunit vaccine only contains the influenza surface antigens HA and 
NA. The virosomal vaccine is a reconstituted viral envelope containing the surface antigens 
HA and NA, but no genetic material. (HA = Haemagglutinin, NA = Neuraminidase, M1 and 
M2 = Matrix proteins). Modified from reference [78]. 
 
1.4.2.6 Virosomal vaccines 
Virosomes are virus-like particles, made from reconstituted influenza viruses. The 
virosomes lack the genetic material and the viral matrix proteins and NP, and can 
therefore not replicate like the native influenza virus. Proper reconstituted viral 
envelopes contain the influenza surface antigens HA and/or NA, and have a retained 
receptor-binding and membrane fusion activity [79]. Thus, the virosomes interact 
extensively with B-lymphocytes, and are presented by APC like the native virus [79]. 
This implies that the antigens are distributed in the cytosol, as well as in endosomal 
compartments, and can therefore be presented by both classes of MHC molecules, 
leading to activation of CD4+ and CD8+ T-cells [80, 81]. Activation of CD8+ T-cells 
is important for the elimination of virus from an infected person. Virosomes have 
been shown to provide enhanced immune responses in elderly and in persons that 
have little or no previous exposure to influenza as compared to subunit vaccines [82, 
83]. Another advantage of the virosomal vaccine is that adjuvants (both amphiphilic 
and lipophilic) can be incorporated in the virosomal membrane [79].  
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Earlier pandemics have shown that children and young adults are at high risk of 
developing severe illness from pandemic influenza [1, 17]. Virosomal vaccines have 
been shown to be both well tolerated and highly immunogenic in children (reviewed 
in [84]), and are therefore favourable for pandemic vaccine formulations. Vaccination 
of elderly people is important both for pandemic and seasonal influenza. Elderly 
people have lower immune responses, primarily due to decreased T-cell activity. 
After influenza vaccination, the immune response shifts toward a Th2 cytokine 
production, which is related to a reduction in CTL activity [85]. Therefore, to make an 
efficient vaccine for elderly, the vaccine should induce both humoral and cellular 
immune responses [86]. A virosomal vaccine could overcome this issue. 
 
1.4.2.7 Mucosal vaccines 
Different routes of administering vaccines mucosally are used today and/or currently 
under investigation. Oral administration of polio and cholera vaccines and intranasal 
administration of influenza vaccines has been used for decades. Mucosal vaccination 
has many advantages over intramuscular vaccination, particularly when it comes to a 
respiratory pathogen such as influenza. When a vaccine is applied at a mucosal site, a 
local as well as a systemic immune response is induced [87]. The mucosal immune 
response in the respiratory tract, represented mainly by IgA, can protect against an 
influenza virus infection at the site of viral entry. It has also been shown that secretory 
antibodies (SIgA) are more cross-reactive against different strains of influenza than 
IgG [88, 89]. A highly cross-reactive vaccine could reduce the need for annual 
vaccination, and render the population immune for a possible future pandemic. The 
avoidance of needles is also beneficial in a number of ways. More people would 
choose to be vaccinated with influenza, including those with needle phobia. Self-
vaccination would be easier, the need for health care personal minimised reducing the 
cost of vaccination. Serious injection-site adverse reactions, such as anaphylaxis 
could be avoided, and the risk of systemic side effects decreased. Today, intranasal 
(IN) influenza vaccines are licensed in USA and Europe [68, 69]. In Switzerland an 
intranasal inactivated virosomal influenza vaccine was withdrawn from the market 
due to an association with a serious side effect called Bell’s Palsy (idiopathic facial 
paralysis) [90]. It has not yet been agreed on whether it was the vaccine antigen or the 
mucosal adjuvant (Escherichia coli heat-labile toxin (LT)) that caused this side 
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reaction, but since intranasal LAIV has not been associated with the same ADR it is 
most likely due to the mucosal adjuvant. However, the nasal epithelium is localised 
close to the CNS, and redirection of viral antigen [91, 92] and mucosal adjuvants (LT 
and cholera toxin) [93, 94] to the olfactory bulb and olfactory nerves after IN 
vaccination of mice has been reported. It is therefore important to investigate new 
ways of administering mucosal vaccines and new mucosal adjuvants that can be used 
both in intranasal and sublingual formulations. 
 
1.4.2.8 Sublingual vaccination 
Sublingual (SL) delivery is the administration of a substance under the tongue (from 
Latin, sub lingua = under the tongue) (figure 1.7). This route of administration have 
been used for decades [95], and today many drugs are administered sublingually. SL 
administration can be used for both local and systemic treatment [96]. In recent years, 
SL tablets have also been used for administration of proteins and peptides, including 
immunotherapy against allergic rhinitis and it is considered as a safe administration 
route (reviewed in [97]). After intranasal vaccination was associated with Bell’s Palsy 
[90], SL influenza vaccination represents a novel and attractive approach as an 
alternative to the intranasal route. In previous studies, SL administration of influenza 
showed no antigen redirection to the olfactory bulb in the brain, therefore minimising 
the risks of neurological side effects like Bell’s Palsy [91, 92]. In addition, no cases of 
anaphylactic shock after SL administration have been reported (reviewed in [98]).  
 
 
Figure 1.7: Sublingual administration 
From reference [99]. 
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1.4.2.9 Vaccine Adjuvants 
Adjuvants are used to improve the immunogenicity of a vaccine. The word adjuvant 
comes from adjvuo, which means help in Latin. Formulations of vaccines with 
adjuvants improves the immune response [100]. Another advantage of adjuvants is 
that they can allow antigen dose sparing, which may be crucial if only limited 
quantities of antigen are available for a pandemic vaccine. The H5 influenza virus 
vaccines have elicited lower immunogenicity in humans than the seasonal vaccines, 
and a good adjuvant is therefore needed [101]. Adjuvants are often classified into two 
groups based on their mechanism of action; delivery systems and immune potentiators 
[102]. The delivery systems often elicit a depot effect, which prolongs vaccine 
antigen presentation to lymphocytes. This can be obtained by increasing the time 
APCs and antigen are exposed to each other at the injection site, or by protecting the 
antigen from breakdown (e.g. liposomes) [100]. The immune potentiators work by 
activating APCs and induce the secretion of pro inflammatory mediators that improve 
the immune response. Activation of APCs most commonly happens through binding 
of PAMPs to PRRs on the APCs and many bacterial and several viral ligands 
therefore could be potential adjuvants. There are also PRR-independent adjuvants that 
can stimulate the immune response [103].  
 
Some frequently used adjuvants are aluminium salts, oil-IN-water emulsions and 
Immune Stimulating Complexes (ISCOMs) and the novel adjuvant used in this 
project, Bis (3’,5’)-cyclic dimeric GMP (c-di-GMP), will be described in the next 
sections. 
Aluminium salts 
Aluminium salts are the most common adjuvant type used in human vaccines, 
including influenza vaccines, and until 2009 it was the only adjuvant type licensed in 
the United States [100, 104]. Different aluminium salts are used, including aluminium 
hydroxide and aluminium phosphate, but often aluminium containing adjuvants are 
called only alum [105]. Even though aluminium salts have been used for decades, 
their mechanism of action is not fully clarified. It has been suggested to have a depot 
effect, so that the antigen is slowly released from the injection site; cause local 
inflammation, attracting APCs to the injection site and activate them; and adsorption 
of antigen to the aluminium salt results in particles and not a soluble antigen, so that 
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uptake into APCs are increased [106]. All these mechanisms have been reviewed in 
[105]. Regarding the activation of DCs, which are the most important APCs, the 
activation seems to occur via a monocytic precursor [107]. In addition, the NLRP3 
inflammasone have been shown to be an important mediator of the alum adjuvant 
effect [108]. The aluminium salts elicits a Th2 skewed response [109]. 
Emulsions (oil in water) 
Emulsions occur when two immiscible liquids are mixed together and held stable by 
an emulsifier. Oil-IN-water emulsions are small droplets of oil dispersed in a watery 
phase. These are effective adjuvants, widely used together with influenza antigens. 
The mechanisms of how these adjuvants work are unknown, but different possible 
explanations could be a depot effect (i.e. the antigen is retained at the injection site), 
local induction of cytokines leading to APC maturation and/or prolonged presentation 
of the antigen to APCs [100]. Oil-IN-water adjuvanted vaccine can also elicit cross-
protective antibody responses, which can be favourable, both in seasonal and 
pandemic vaccines [110-113].  
 
There are different preparations of oil-IN-water emulsions. An MF59 adjuvanted 
vaccine is licensed in Europe [114]. The use and safety issues regarding MF59 is 
reviewed in [100] and it has shown to be an adjuvant with good immune stimulating 
effect and good safety profile [115]. Another oil-IN-water emulsion is AS03. This 
preparation is also showing potent adjuvant activity in combination with influenza 
virus antigen [100, 116], and was used in the pH1N1 vaccine (Pandemrix®) [117]. 
However, an increased incidence of narcolepsy in children has been reported in 
Finland after mass vaccination with Pandemrix® [118], thus questioning the safety of 
AS03.  
ISCOMs and ISCOMATRIX 
ISCOMs (Immune Stimulating Complexes) were first described in 1984 as “A novel 
structure for antigenic presentation of membrane proteins from enveloped viruses” by 
Morein et al. [119]. ISCOMs are composed of quillaia saponin, cholesterol, 
phospholipids and an associated antigen (e.g. influenza antigen) [120]. 
ISCOMATRIX® is ISCOM without the incorporated antigen. It has been shown that 
both ISCOMs and ISCOMATRIX® can elicit both humoral and cellular immune 
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responses [121] and the mechanism of action classifies ISCOMs as both immune 
potentiators and delivery systems [120] (classification by O’Hagan and Valiante 
(2003)[102]). The ISCOMATRIX® adjuvant has been evaluated in human clinical 
trials, and it was found to have an acceptable safety profile. In addition, no 
autoimmune or anaphylactic reactions were reported [120, 122]. A novel generation 
of ISCOMs, the Matrix-M, has been found to potentiate the immune response 
following vaccination with influenza H5N1 virosomes in murine models [123, 124]. 
C-di-GMP 
Bis (3’,5’)-cyclic dimeric GMP (c-di-GMP) is a bacterial intracellular signalling 
molecule. It has been identified in several different bacterial species, but not in higher 
eukaryotes. Therefore, c-di-GMP presumably works as a danger signal to the innate 
immune system. C-di-GMP has been shown to be an effective adjuvant (reviewed in 
[125]), and it has also shown good potential as a mucosal adjuvant [126]. C-di-GMP 
has significant immune stimulatory properties, and stimulates both humoral and 
cellular responses. In vitro it can stimulate DC expression of MHC class II, co-
stimulatory molecules B7-1/B7-2 and maturation marker CD83 [127]. It also induces 
production of pro-inflammatory cytokines and chemokines. In vivo, c-di-GMP has 
been shown to recruit monocytes and granulocytes [127]. The exact mechanisms of 
action still remain unknown, but it has been proposed that c-di-GMP is detected in the 
cytosol by immunosurveillance pathways, similar to those that sense DNA in the 
cytosol [128]. The safety profile in vivo has not yet been assessed for the c-di-GMP 
adjuvant. However, in vitro studies show no lethal cytotoxicity in rat kidneys cells or 
in human neuroblastoma [125].  
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1.5 Aims of the study 
 
Mucosal immunisation provides local immunity, which can prevent influenza 
infection at the portal of entry. In addition, mucosal vaccines can be administered 
without the use of needles, and are thus attractive for use in developing countries. 
Intranasal influenza vaccines have been used for decades, but the only licensed 
adjuvanted intranasal vaccine was withdrawn from the market due to the association 
with Bell’s Palsy (a facial nerve paralysis). Vaccination under the tongue (sublingual 
vaccination) may provide a safe alternative to intranasal vaccination and requires 
further investigation.  
 
Mucosal vaccines have earlier been shown to induce a weak immune response when 
administered without an adjuvant. Virosomes (virus like particles) are more 
immunogenic than subunit vaccines [82],  and also induce cell-mediated immunity 
[81].To further boost the immune response we combined a virosomal vaccine with the 
promising mucosal adjuvant c-di-GMP. 
 
The aim of this study is to evaluate the sublingual route for administration of an 
H5N1 virosomal influenza vaccine, alone and in combination with the promising 
mucosal adjuvant c-di-GMP. Therefore we compared the immunogenicity induced by 
sublingual, intranasal and intramuscular administration of the vaccines in mice. Both 
the local and systemic humoral response and cellular immunity were studied. 
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2 Materials 
 
Name        Supplier 
2.1 Mice 
BALB/c – 6-8 weeks old, albino, female    Charles River Laboratories,  
Germany  
 
2.2 Vaccines and viruses 
Influenza H5 virosomal vaccine, 322 µg HA/mL 
(A/Vietnam/1194/2004 (H5N1)) NIBRG-14 
 
Crucell B.V., Holland 
 
2.3 Anaesthetics and other drugs 
Rompun® Vet (Xylazine) (20 mg/mL)    Bayer, Germany 
Ketalar (Ketamine) (50 mg/mL)     Pfizer, USA  
Pilocarpine HCL (0.125 mg/mL), P6503-5g    Sigma, USA 
Euthanasia:   
CO2-chamber       Scanbur A/S,              
     Denmark 
2.4 Blood 
Turkey red blood cells (10 %) in PBS National Institute for Biological 
Standards and Control (NIBSC), United 
Kingdom 
 
 
2.5 Antibodies 
Name                Catalogue number Supplier 
Capture antibodies        
Goat anti-mouse IgA (1 mg/mL)  1040-01   SouthernBiotech, USA 
Goat anti-mouse IgG (1 mg/mL)  1030-01   SouthernBiotech, USA 
Goat anti-mouse IgG1 (1 mg/mL)  1070-01   SouthernBiotech, USA 
Goat anti-mouse IgG2a (1 mg/mL)  1080-01   SouthernBiotech, USA 
 
Immunoglobulin standards         
Mouse IgA (1 mg/mL)   M1421   Sigma, USA  
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Mouse IgG (1 mg/mL)   15381   Sigma, USA 
Mouse IgG2a (1 mg/mL)   M9144   Sigma, USA 
Mouse IgG1 (0.5 mg/mL)   0102-14   SouthernBiotech, USA 
 
 
Biotinylated antibodies       
Goat anti-mouse IgA (0.5mg/mL)   1040-08   SouthernBiothech, USA 
Goat anti-mouse IgG (0.5mg/mL)  1030-08   SouthernBiothech, USA 
Goat anti-mouse IgG1 (0.5 mg/mL)  1070-08   SouthernBiothech, USA 
Goat anti-mouse IgG2a (0.5 mg/mL) 1080-08   SouthernBiothech, USA 
Goat anti-mouse pIgR (0.5 µg/mL)  BAF 2800  R & D Systems 
 
Fluorophore-conjugated antibodies      
Rat anti-mouse CD8   557654   BD Biosciences, USA 
Rat anti-mouse CD4   553047   BD Biosciences, USA 
Rat anti-mouse IFN-γ   554413   BD Biosciences, USA 
Rat anti-mouse IL-2   554428   BD Biosciences, USA 
Rat anti-mouse TNF   557644   BD Biosciences, USA 
Hamster anti-mouse CD3e   551163   BD Biosciences, USA 
 
 
2.6 Reagents and chemicals 
            
Name Cat. No Supplier 
Anti-CD28 (Hamster anti-mouse) 553294 BD Biosciences, USA 
BD FCblock™ (mouse) 553142 BD Biosciences, USA 
BD CompBeads Negative Control (FBS) 51-90-9001291 BD Biosciences, USA 
BD CompBeads Anti-rat 51-90-9000949 BD Biosciences, USA  
Bovine serum albumin (BSA) A-6793 Sigma, USA 
Casy®Ton  043-90037P Schärfe System GmbH, 
Germany  
Citric acid monohydrate (C6H8O7·H2O) 1.00244 Merck, Germany 
Dimethylformamide (DMF) 10322  BHD AnalaR, England 
Di-sodium hydrogen phosphate anhydrous 
(Na2HPO4)  
1.06586 Merck, Germany  
Extravidin Peroxidase (Extravidin PO) E-2886 Sigma, USA 
Fix/Perm solution (BD Cytofix/Cytoperm) 51-2090KZ BD Biosciences, USA 
Foetal bovine serum (FBS) 14-701F Bio Whittaker, Belgium  
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Foetal bovine serum (FBS) Gold A15-151 PAA, Austria 
Glacial acetic acid (C2H4O2)  1-06268 Merck, Germany 
Golgi plug 51231KZ BD Biosciences, USA 
Hepes buffer (1M) H0887  Sigma, USA 
Hydrogen peroxide, H2O2, 30 % H1009  Sigma USA 
Ionomycin 10634  Sigma, USA 
Lymphoprep ™   1114545 Axis-Shield PoC A/S, 
Norway  
Minimal Essential Medium (MEM) non essential 
amino acids (100x) 
11140-035 GIBCO, UK  
Mercaptoetanol (2-ME) M-7522 Sigma, USA 
Newborn Calf Serum (NCS)  ECS0070L Euroclone, Italy  
Ortho-phenylediamine dihydrochloride (OPD, 10 
mg) 
P-8287 Sigma, USA 
Pansorbin 507858 Calbiochem/Merck, USA 
Penicillin/Streptomycin/Amphoterecin (PSA) 17-745E Bio Whittaker, Belgium 
PMA (phorbol myristate acetate) P8139 Sigma, USA 
Pokeweed mitogen L8777 Sigma, USA 
Potassium di-hydrogen phosphate (KH2PO4) 1.04847 Merck, Germany 
Receptor destroying enzyme (RDE) 340122 Denka Seiken CO, Japan 
RPMI (Roosewell Park Memorial Institute) medium 21875-034 GIBCO, UK  
Sodium acetate trihydrate (CH3COONa) 1-06267 Merck, Germany 
Sodium Azide S8032-25G Sigma, USA 
Sodium chloride (NaCl) 1.06404 Merck, Germany 
Sodium pyruvate (100 mM) S8636  Sigma, USA 
Sulphuric acid 18.4 M (H2SO4) 112080 Merck, Germany 
TMB-H Peroxidase substrate 01028101 Moss, inc., USA 
Tween 20: Polyoxylene-Sorbitan monolaurate P-1379  Sigma, USA  
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2.7 Bio-plex Kits 
Mouse Cytokine Grp I X-Plex Assay      Bio-Rad Laboratories, 
(Cytokine 7-plex - IL-2, IL-4, IL-5, IL-10, IL17, IFN-γ, TNF-α)  USA 
Cat. No X6000006RJ     
Bio-plex Reagent Kit    (171-304000)    
Bio-plex Calibration Kit   (171-203060)    
 
 
2.8 Plates/equipment 
Name 
Elisa plates, F-bottom    (655001)         Greiner, Germany 
Elispot – Multiscreen®, HA plates   (MAHA N45 50)         Millipore, UK 
Cell-culture plates, Nunclon™ surface  (143982)                      Nunc Brand Products, DK 
Multiplex – Multiscreen®, HTS™, BV  (MSBVN1250)         Millipore, UK 
HI – V96 MicroWell™ Plates   (249570)         Nunc Brand Products, DK  
Nunc Immuno™ Wash 12 Plate washer            Nunc Brand Products, DK 
Microvette® CB 300- System for capillary  (16.440.100)         Sarstedt, Germany  
blood collection    
         
2.9 Instruments: 
Name                 Supplier    
BD FACS Canto ™ Flow Cytometer (No.337175) BD Biosciences, USA 
Bio-Plex ™ 200 System Powered by Luminex XMAP ™ 
Technology 
Bio-Rad Laboratories, USA 
CASY® Cell Counter Schärfe System GmbH, Germany 
ELISA plate reader, Multiscan MS Labsystems, USA 
Forma Scientific” bio-freezer Forma 8438 (-80°C) LabTrader, USA 
Heidolph Titramax 100 Vibrating platform shaker Heidolph Instruments, Germany 
Immunoscan ™ Elispot reader C.T.L Europe GmbH, Germany 
Microplate washer, ELx450 HT BioTek, USA 
Knf Lab Laboport vacuum pump Bio-Rad Laboratories, USA 
 
Centrifuges: 
  
Heraeus Labofuge 400R – FunctionLine Thermo Scientific 
Eppendorf Centrifuge 5810 R (no. 0036331) Eppendorf International 
Eppendorf Centrifuge 5424, 230V (no. 0006928) Eppendorf International 
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2.10 Computer Software  
Ascent Software Version 2.6 (ELISA)     Labsystems, USA 
Program BioPlex manager 5 (Multiplex)    Bio-Rad, USA 
FlowJo    (Intracellular cytokine staining)  TreeStar inc., USA 
ImmunoSpot 4.0 Academic and Immunoscan Professional (ELISPOT) C.T.L, Europe, 
Germany 
2.11 Solutions, buffers, medium 
Mouse Lymphocyte medium (MLM), 100 mL 
• 86 mL RPMI 1640 medium supplemented L-glutamine 
• 1 mL 10 mM nonessential amino acids 
• 1 mL 1 M Hepes pH 7.4 
• 1 mL 100 mM sodium pyruvate 
• 1 mL PSA 
• 100 µL 5x10-5 M 2-ME 
• 10 mL heat-inactivated FBS Gold 
 
10x Phosphate Buffered Saline (PBS) 1L 
• 85 g NaCl 
• 2.50 g KH2PO4 
• 6.85 g NaHPO4 
Add dH2O to a total volume of 1000 mL. pH should be 7.4 ± 0.2 
 
PBS/NCS (20 %) 250 mL 
• 50 mL NCS (newborn calf serum) filtered through a 0.45 µm filter to 200 mL sterile PBS 
 
PBS/FBS (5 %) 250 mL 
• 12.5 mL FBS (foetal bovine serum) to 237.5 mL sterile PBS 
 
1x PBS/Tween 0.05% (5 L) 
• Dilute 0.5 L sterile 10x PBS in 4.5 L dH2O 
• Add 2.5 mL Tween 20 
 
PBS/BSA (0.05%) 50 mL 
• 0.025 g BSA (bovine serum albumin) to 50 mL sterile PBS 
 
Cell count mixture 
• 10 mL Casy®Ton mixture 
• 20 µl isolated cell suspension 
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Intracellular cytokine staining 
Mitogen medium 
• 1 mL negative control medium 
• 2 µl PMA (10 ng/mL) 
• 5 µl Ionomycin (250 ng/mL) 
Influenza medium 
• 1 mL (A/Vietnam/1194/2004 (H5N1) NIBRG-14) virosome (2.5µg HA/mL) in MLM 
• 2 µl Golgi plug (Brefeldin A)  
• 2 µl anti-CD28  
Negative control medium 
• 1 mL MLM 
• 2 µl Golgi plug (Brefeldin A)  
• 2 µl anti-CD28 
Flow medium (FM) 
• 93 mL PBS 
• 5 mL FBS 
• 2 mL Sodium Azide 5% (w/v) (5 g Sodium Azide in 100 mL milli-Q H2O) 
Perm wash solution (PW) 
• 10 mL Perm Wash 
• 90 mL ddH2O 
 
In vitro activation of lymphocytes 
Mitogen medium 
• 1 mL negative control medium 
• 2 µl PMA (10 ng/mL) 
• 5 µl Ionomycin (250 ng/mL) 
Influenza medium 
• 1 mL (A/Vietnam/1194/2004 (H5N1) NIBRG-14) virosome (2.5µg HA/mL) in MLM 
Negative control medium 
• 1 mL MLM 
 
ELISPOT solutions 
2X mitogen mix 
• 4.8 mL MLM 
• 100 µl Pansorbin, washed and diluted 1:100 in MLM 
• 100 µl Pokeweed mitogen, diluted 1:100 in MLM 
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ELISA solutions 
Di-sodium hydrogen phosphate 0.2 M (1L) 
• 28.30 g di-sodium hydrogen phosphate (Na2HPO2) 0.2 M 
      Add ddH2O to 1000 mL 
Citric acid 0.1 M (1L) 
• 21.01 g citric acid monohydrate (C6H8O7H2O). Add ddH2O to 1000 mL   
Phosphate citrate buffer (pH 5.0 – 1L) 
• 257 mL 0.2 M Na2HPO2 
• 243 mL 0.1 M C6H8O7·H2O. Add ddH2O to 1000 mL  
 OPD (Ortho-phenylediamine dihydrochloride)  solution  
• Solve 10 mg OPD in 25 mL phosphate citrate buffer 
• Add 20 µl H2O2 immediately before adding to plate. Keep dark 
1M H2SO4 (1L) 
• 54.40 mL 18.4M sulphuric acid 
• 949.50 mL ddH2O 
 
2.12 Disposable consumables   
Acetate foil for microtest well plates (82.1586)    Sarstedt, Germany   
Centrifuge tube 15 mL      VWR International, USA 
Elisa dilution tubes 1.3 mL (102270)    Greiner Bio-One, Germany 
Falcon tubes 50 mL      BD Labware, USA 
Microtubes 0.5 mL      Sarstedt, Germany  
Microtubes 1.5 mL      Axygen Biosciences, USA  
Needles, 23 G, 21 G       Braun, Germany 
Paper towels for Elisa and Elispot     VWR International, Norway 
Petri dishes (90 mm) 391-0875     VWR International, Norway 
Pipettes        Thermo Labsystems 
Scalpels No 22       VWR International, Norway 
Syringe (vaccination) Micro-Fine ™ 0.3 mL (320830)   BD Biosciences, USA 
Syringe 1 mL BD Plastipak 300013     BD Medical, Spain 
Syringe 2 mL BD Plastipak 300186     BD Medical, Spain 
Syringe 50 mL BD Plastipak 300866    BD Medical, UK 
Syringe Filter 0.45 µm      Millipore, DK 
Syringe Filter 0.20 µm      Whatman, UK 
Thermo Labsystems Finnpipette Novus, multichannel  Termo Scientific, USA 
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3 Methods 
 
3.1 Experimental protocol 
3.1.1 Mice 
Forty-two BALB/c female mice (6-8 weeks old) were acclimatized in their cages for 
seven days and were housed at 21°C and with 12-hour light/dark cycles. Mice were 
divided into groups of six mice according to a numerical system. Each group was 
vaccinated with the NIBRG-14 virosomal vaccine (2µg HA) either intramuscularly 
(IM), intranasally (IN) or sublingually (SL) with or without adjuvant (c-di-GMP (7.5 
µg)) (table 3.1). One group was given only adjuvant as a control and PBS IN. 
Immunisation, sampling and euthanasia were carried out at shown in figure 3.1. All 
handling of the mice was carried out according to The Norwegian Regulation on 
Animal Experimentation (“Forsøksdyrforskriften”), and approved by the national 
Animal Research Committee (approval No. 2010-2742).  
 
 
Figure 3.1: Vaccination and sampling timeline 
BALB/c mice received two doses of virosomal influenza A/Vietnam/1194/2004 (H5N1) 
NIBRG-14 vaccine intramuscularly (IM), sublingually (SL) or intranasally (IN) with (+) or 
without (-) adjuvant three weeks apart. C-di-GMP in PBS was administered IN to controls 
(C). Peripheral blood (PB) and nasal wash (NW) were collected at days 7, 20 and 35 post first 
immunisation. NW was also collected at day 41 (the day before the sacrifice). Saliva, cardiac 
blood (CB) and spleens were collected on the sacrifice day. 
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Table 3.1: Overview of vaccination groups 
A total of 42 BALB/c mice were vaccinated, divided into groups of six. One group received 
only c-di-GMP as controls. (+) indicates with adjuvant, (-) indicates no adjuvant. 
Administration route c-di-GMP 
Intramuscular (IM)  + (6 mice)  - (6 mice) 
Intranasal (IN)  + (6 mice) - (6 mice) 
Sublingual (SL)  + (6 mice)  - (6 mice) 
Control (adjuvant only) (C)  + (6 mice)  
 
 
3.1.2 Virosomal vaccine 
The vaccine strain used in this study was influenza H5 NIBRG-14, derived from 
A/Vietnam/1194/2004 (H5N1). The strain was produced using reverse genetics, and 
the virus was grown in the allantoic cavity of embroynated hen’s eggs. The vaccine 
was formulated as virosomes at Crucell where the virus was inactivated using beta-
propiolactone and a detergent (octaethyleneglycol monododecylether) was used to 
solubilise the HA, NA and phospholipids of the virus. Next the surface antigens NA 
and HA were purified and mixed with the phospholipid component lecithin. The 
virosomes were then generated by the stepwise removal of detergent followed by a 
spontaneous incorporation of HA and NA into the phospholipid bilayer. 
 
3.1.3 Adjuvant 
The adjuvant used was bis (3’,5’)-cyclic dimeric GMP (c-di-GMP) provided by 
Helmholtz Centre for Infection Research, Germany. This is a chemical compound 
synthesized according to established protocols [129, 130], and purified by high-
performance liquid chromatography as described by Ebensen et al. [126].  
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3.1.4 Vaccination 
Intranasal vaccination 
Both SL and IN vaccinations were carried out on anesthetised mice. The anaesthesia 
used was a 160 µl mixture of xylazine (Rompun Vet®) 1 mg/mL and ketamine 
(Ketalar®) 10 mg/mL in sterile PBS given subcutaneously. After approximately 10-
15 minutes the mice were checked for level of narcosis. For IN administration the 
mice were placed in supine position, and 3.5 µl vaccine was administered into each 
nostril using a thin micropipette, giving a total volume of 7 µl vaccine (2 µg HA of 
virosomal vaccine with or without 7.5 µg of c-di-GMP adjuvant). After vaccine 
administration, the mice were kept in the same position for at least 5 minutes to make 
sure the vaccine was absorbed (figure 3.2).   
 
 
Figure 3.2: Intranasal vaccination 
When anesthetised, the mice were placed in supine position and 3,5 µl of vaccine (2 µg HA of 
virosomal vaccine with or without adjuvant) was applied into each nostril. The mice were 
kept in supine position for at least 5 minutes after application of the vaccine, to allow vaccine 
absorbance. 
 
Sublingual vaccination 
For SL administration the mice were held in a head-up vertical position as illustrated 
(figure 3.3.), and a micropipette was used to apply 7 µl vaccine (2 µg HA of 
virosomal vaccine with or without 7.5 µg of c-di-GMP adjuvant) under the tongue. 
After application the mice were placed in anteflexion (sitting with their head bend 
over their lower extremities) for at least 20 minutes after vaccination to prevent the 
mice from swallowing the vaccine.  
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Figure 3.3: Sublingual vaccination 
When anesthetised, the mice were held in a head-up vertical position as illustrated, and 7 µl 
vaccine (2 µg HA of virosomal vaccine with or without 7.5 µg of c-di-GMP adjuvant) were 
placed under the tongue of the mice.  
 
Intramuscular vaccination 
For IM vaccination the mice were restrained in 50 mL plastic tubes, which had been 
punctured in advance. The hind leg was exposed and 50 µl of vaccine (2 µg HA of 
virosomal vaccine with or without 7.5 µg of c-di-GMP adjuvant) was injected 
intramuscularly into the quadriceps muscle.  
 
3.1.5 Collection of Venous Blood 
The saphenous vein on the hind leg was used to obtain blood samples (figure 3.4). 
The mice were placed in a plastic tube and the hind leg was exposed. The fur over the 
vein was removed using a scalpel before the vein was punctured with a needle. A 
microvette capillary was used to collect 50-100 µl of blood from each mouse on each 
blood-sampling day.  
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Figure 3.4: The saphenous vein used for blood sampling 
The hind leg was first gently shaved to expose the vein. A needle was used to puncture the 
vein and the blood collected in a microvette capillary. The picture was kindly provided by 
Monica Trondsen. 
 
3.1.6 Collection of Nasal Wash 
Mice were restrained by holding them in the scruff upside-down over a petri dish 
(figure 3.5). To collect samples from the nasal cavity, 350 µl sterile PBS/BSA 0.05% 
was flushed from the mouth through the nostrils of the mice using a 1 mL syringe and 
a feeding tube. Two flushings were performed before the samples were collected in a 
microtube and put on ice. The samples were frozen at -80°C until used in the ELISA 
assay (3.2.2). 
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Figure 3.5: Collection of nasal wash 
The mice were held steadily upside-down over a petri dish, the nasal cavity flushed with 350 
µl PBS/BSA (0.05%) twice. The picture was kindly provided by Monica Trondsen. 
 
3.1.7 Collection of Saliva 
On the sacrifice day, mice were anesthetized with 120 µl mixture of xylazine 
(Rompun Vet®) 1 mg/mL and ketamine (Ketalar®) 10 mg/mL in sterile PBS given 
subcutaneously. After anaesthesia had occurred, 10 µg pilocarpine in 80 µl PBS was 
given intraperitoneally and each mouse was placed in a petri dish. After 
approximately 5 minutes the mice started secreting saliva, and up to 50 µl saliva from 
each mouse was collected with a micropipette. The samples were frozen at -80°C 
until used in the HI (3.2.4) and ELISA (3.2.2) assays. 
 
3.1.8 Collection of Cardiac Blood and Tissue 
Mice were euthanized using CO2, and fastened to a dissection plate with pins. Cardiac 
puncture was performed directly after euthanasia, and the cardiac blood was collected 
in an Eppendorf tube using a 23 G needle and a 2 mL syringe. Next, the spleen and 
cervical lymph nodes were aseptically dissected out and transferred to tubes 
containing sterile PBS/FBS.  
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3.1.9 Separation of sera 
The blood samples were left in the fridge for 2-3 hours to clot. The clotted blood was 
centrifuged at 845 g for 10 minutes. Then sera were isolated, transferred to 
microtubes and frozen at -80°C until used in the HI (3.2.4) and ELISA (3.2.2) assays.  
 
 
3.2 Immunological assays 
 
3.2.1 Isolation of lymphocytes 
Lymphocytes were isolated from the spleen. All work with lymphocytes was carried 
out in a laminar airflow cabinet using aseptic techniques.  
 
Spleen 
The spleen was placed in a petri dish and dichotomised using two bent 21 g needles. 
Splenocytes were washed out of the spleen and flushed with PBS/FBS until a volume 
of 6 mL cell suspension was obtained.  
 
Lymphoprep 
Lymphocytes were separated on three mL of lymphoprep in a 15 mL centrifuge tube, 
layering 6 mL of cell suspension carefully on top of the lymphoprep. The tube was 
centrifuged at 800 g for 30 minutes at room temperature with the centrifuge brake off. 
After centrifugation the distinct band of mononuclear cells was transferred into a new 
15 mL centrifuge tube. The lymphocytes were washed (290 g for 10 minutes at 4°C) 
twice in PBS/FBS (5%). The splenocytes were re-suspended in 2 mL lymphocyte 
medium, respectively. The cells were counted using a CASY® cell counter. Cell 
suspensions were adjusted to 1x107 cells/mL by adding lymphocyte medium.  
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3.2.2 Antibody ELISA 
ELISA (Enzyme linked immunosorbent assay) is an immunological method used for 
detection and quantification of antibodies. The method is based on antigen-antibody 
interactions and a secondary biotinylated antibody that can bind an enzyme-linked 
avidin with specificity for biotin. A colorimetric substrate allows measurement of 
concentration of influenza-specific antibodies, using spectrophotometric equipment. 
 
ELISA-plates were coated with 100 µl/well of 2 µg/mL of influenza H5 NIBRG-14 
virosomal antigen or 1/1000 capture antibody (IgG, IgG1, IgG2a or IgA) diluted in 
sterile PBS. The plates were incubated at 4°C overnight. The next morning, the 
coating solution was removed and plates were blocked with 200 µl/well with 
PBS/NCS (20 %) for 1 hour at room temperature.  Sera and antibody standards were 
diluted (5-fold and 2-fold dilutions starting at 50 ng/mL, respectively) in PBS/NCS 
(20%). Wells were emptied of blocking solution (flicked out in the sink) and 100 
µl/well of serum and standard dilutions were added in duplicate. The plates were 
incubated for 1.5 hours at room temperature. After incubation, the plates were washed 
6 times in PBS/Tween (PBS/T) 0.05% using the Microplate washer. Next, 100 µl/well 
of goat anti-mouse (IgG, IgG1, IgG2a, IgA or pIgR) specific-biotinylated antibody 
diluted 1/500 (1/50 for pIgR) in PBS/NCS (20%) was added and the plates were 
incubated for 1 hour at room temperature. After incubation, the plates were washed 6 
times as described above. Then, 100 µl/well of Extravidin PO diluted 1/1000 in 
PBS/NCS (20%) was added and the plates were incubated for 1 hour at room 
temperature. Again, the plates were washed 6 times as previously described. The OPD 
substrate was prepared by adding 1 tablet (10 mg) of OPD to 25 mL 0.05M phosphate 
citrate buffer pH 5, protected from light. Immediately before adding the OPD-
substrate to the plate, 20 µl H2O2 were added to the solution. One hundred µl/well of 
OPD-substrate was then added to the plate. After 10 minutes incubation in the dark, 
the reaction was stopped with 100 µl/well of 1M H2SO4. Subsequently, the 
absorbance (OD) at 492 nm was read using the ELISA plate reader and the Ascent 
software. The background (OD-values in blank wells) was subtracted from all values 
and standard curves were prepared as log-log graphs in the Ascent program using 
linear regression (R>0.99). These standard curves were used to calculate the 
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influenza-specific antibody concentration (in ng/mL and µg/mL) in serum, nasal wash 
and saliva by interpolation. For pIgR, no standard was available and the results are 
only given in OD-values (absorbance at 492 nm). 
 
3.2.3 Memory B-cell ELISPOT 
Memory ELISPOT is used to detect and quantify antibody-secreting memory B-cells 
in splenocytes and lymph node cells after polyclonal stimulation with mitogen. The 
protocol was adapted from [131]. Total IgG specific and influenza antigen-specific 
memory cells were determined. 
 
Splenocytes were isolated as described in section 3.2.1. The lymphocytes were diluted 
to 1 x 106 cells/mL in mouse lymphocyte medium (MLM) and 0.5 mL cell suspension 
was added to each well of a 24-well Nunclon™ Surface plate. Each sample was added 
to four wells (two for mitogen stimulation and two for non-stimulated controls) and 
the plates were incubated at 37°C with 5% CO2 whilst preparing the mitogen mixture. 
A 2x mitogen mix was made up in MLM, 0.5 mL was added to two of the four wells 
per sample, the remaining two wells were non-stimulated control wells and 0.5 mL 
MLM was added. The plates were wrapped in plastic to limit evaporation and 
incubated for 6 days at 37°C with 5% CO2. On day 5, 96-wells ELISPOT plates were 
coated with 100 µl/well of 2 µg/mL influenza antigen (RG-14 virosomes) and 1:500 
of anti-mouse IgG, diluted in sterile PBS. One hundred µl/well of sterile PBS was 
added to one row to serve as a negative control. The plates were incubated overnight 
at 4°C. The next day, the coating-solution was flicked out, and the plates were 
blocked with 150 µl/well of MLM for at least 2 hours at 37°C with 5% CO2. Both 
stimulated and non-stimulated cells were re-suspended and collected in 15 mL tubes 
and centrifuged for 10 minutes at 300g at 4°C. Each pellet was re-suspended in 10 mL 
lymphocyte wash medium (LWM) and again centrifuged for 10 minutes at 300g at 
4°C. The supernatant was removed and each pellet was re-suspended in 2 mL MLM 
and centrifuged for 10 minutes at 300g at 4°C. The supernatant was removed and 
each pellet was re-suspended in 4 mL MLM (final concentration of 25000 
cells/100µl). The blocking buffer was flicked out of the ELISPOT plate and 100 
µl/well of MLM was added to each well. Subsequently, re-suspended cells were 
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added (100 µl/well) to the top row of the plate, and 2-fold diluted down the plate. The 
final row was left blank (no cells) as a negative control. Splenocytes were added to 
the plates coated with RG-14/anti-mouse IgG. The plates were incubated overnight 
(16-20 hours) at 37°C and 5% CO2. The next day, the plates were washed once with 
PBS (to avoid cell lysis) and six times with PBS/T (0.05%). The first four washes 
were quick to avoid cross-contamination between wells. For the last two washes the 
plates were soaked for 2-5 minutes and a vacuum was used to suck PBS/T through the 
plates. After washing, 100 µl/well of biotIN-conjugated goat anti-mouse IgG diluted 
1:1000 in PBS/T and filtered through a 0.2 µm syringe filter were added to the plates. 
Plates were then incubated for 2 hours at room temperature. Subsequently, 100 µl of 
filtered extravidIN-PO in PBS/T (1:1000) was added to each well and incubated for 1 
hour at room temperature. The plates were washed again as previously described. The 
reaction was developed with 100 µl/well of TMB-H for approximately 5 minutes, and 
the plates were washed thoroughly under running tap water to stop the reaction. Plates 
were left to dry in the dark for 2 days. The membranes were punched out on sealing 
tape, the wells scanned and spots were counted using the ELISPOT Immunospot 
reader. Any spots in negative control wells were subtracted from corresponding 
antigen-stimulated wells. 
 
3.2.4 Haemagglutination Inhibition Assay 
Treatment of sera 
Receptor-destroying enzyme (RDE) solution was reconstituted in 20 mL sterile 
according to the manufacturers’ instructions. Sera and saliva were diluted 1:5 and 1:1 
in RDE and incubated at 37°C overnight to remove nonspecific inhibitors of 
haemagglutination. The remaining RDE was heat inactivated by further incubation at 
56°C for 30 minutes and sera were cooled to room temperature before use. 
Preparation of turkey red blood cells (RBC) 
Turkey red blood cells were washed repeatedly (167 g for 10 minutes at 4°C) until the 
supernatant was clear (no haemolysed RBC). A 0.7 % v/v RBC suspension was 
prepared by adding cold PBS.  
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Virus titration (Haemagglutination assay) 
An initial virus titration was performed to determine the appropriate dilution of virus. 
For the haemagglutination assay 50 µl PBS was added to each well of a V-well 
bottom microtitre plate. Then, 50 µl virus suspension was added to the first row, and 
2-fold diluted across the plate with the final 50 µl being discarded. Then 50 µl of 0.7 
% turkey RBC was added to each well and the plate was incubated for 30 minutes at 
room temperature. The titre was read as the reciprocal of virus dilution that gave 50 % 
agglutination. The virus titre was adjusted to be 8 HA units (HAU)/50 µl.  
Haemagglutination inhibition test 
50 µl PBS was added to each well on a V-well bottom microtitre plate. Then 50 µl of 
RDE-treated sera/saliva was added to the first row, and 2-fold diluted across the plate, 
the final 50 µl being discarded. Then 50 µl of standardized virus (8 HAU/50 µl) was 
added to each well and the plate incubated at room temperature for 1 hour. Thereafter 
50 µl 0.7 % turkey RBC was added to each well and the plate was incubated for 30 
minutes before readout.  The haemagglutination inhibition titre (HIT) was read as the 
reciprocal of the serum dilution that gave 50 % agglutination.  
 
3.2.5 In vitro activation of lymphocytes 
The cytokine response from isolated splenocytes can be detected after in vitro 
stimulating cells with influenza antigen. Cytokines accumulate in the supernatant and 
the concentration can be measured by Illuminex assay.  
 
Influenza A/Vietnam/1194/2004 (H5N1) virosomal antigen diluted in lymphocyte 
medium to a final concentration of 2.5 µg HA/mL, mitogen medium (PMA and 
ionomycin) and negative control medium (medium alone) were prepared and 100 
µl/well added to a 96-wells flat-bottom tissue culture plate. Next, 100 µl/well of cell 
suspension containing 1.0×106 lymphocytes, was added to the plate. The plate was 
incubated for 72 hours at 37°C with 5% CO2. After incubation, 200 µl from each well 
was transferred to a 96-well V-shaped bottom plate and centrifuged for 10 minutes at 
300 g. Supernatants were then transferred to a new plate and frozen at -80°C until 
tested in the multiplex bead assay (3.2.6).  
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3.2.6 Multiplex bead assay 
The multiplex assay was used to determine the concentration of IL-2, IL-4, IL-5, IL-
10, IL-17, IFN-γ and TNF-α from supernatants of in vitro stimulated splenocytes 
according to the manufacturers’ protocol (Bio-Rad, USA). Cytokine standards were 
diluted 4-fold and put on ice until used. 575 µl of 10x coupled beads stock was diluted 
in 5.175 mL Assay Buffer, gently vortexed and 50 µl were added to each well. Next, 
the plate was washed with wash buffer (100 µl/well) twice by suction. After the wash, 
50 µl of each standard and 50 µl of each sample were added to the appropriate wells. 
Two wells served as blanks containing cell medium alone. The plate was then sealed 
with a plastic adhesive film and left to incubate in the dark for 30 minutes on a 
platform shaker (300 rpm). Subsequently, 300 µl detection antibody was diluted in 
2700 µl detection antibody diluent. The plate was washed three times by suction and 
25 µl diluted detection antibody was added to each well. The plate was incubated as 
described above for 30 minutes. Again the plate was washed three times by suction. 
Sixty µl StreptavidIN-PE was diluted in 5 940 µl Assay Buffer A, and 50 µl were 
added to each well. The plate was incubated as described above for 10 minutes and 
washed three times by suction. Subsequently, 125 µl of Assay Buffer was added to 
each well, the plate was sealed and the beads re-suspended by shaking at 1100 rpm 
for 30 seconds. Thereafter the plate was read on the luminex instrument and a 
standard curve was created using Bioplex Manager 5.  
 
3.2.7 Intracellular cytokine staining 
Lymphocytes produce cytokines upon antigen presentation by an APC. By blocking 
the Golgi apparatus of the lymphocytes, antigen-specific cytokines accumulate inside 
the cells and can be measured by intracellular cytokine staining using flow cytometry. 
 
Splenocytes were isolated (3.2.1), and the cell concentration was adjusted to 
1.0×107/mL. One hundred µl of the appropriate medium (influenza medium (RG-14 
virosomal antigen, diluted to a concentration of 2.5 µg HA/mL in MLM), mitogen 
medium or negative control medium) and 100 µl of cell suspension was added into 
each well of a 96-wells-flat bottom tissue culture plate and incubated for 17 hours at 
37°C with 5% CO2.  
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Fixation and staining 
The cells were transferred to a 96-wells V-shape well plate and centrifuged at 240 g 
for 5 minutes at 4°C.  After centrifugation, the cells were washed twice with 200 µl 
Flow Medium (FM) and centrifuged as described above. The supernatants were 
removed and the cells re-suspended well. Next, 100 µl of 10 µg/mL BD FCblock™ in 
FM was added and the plate incubated for 15 minutes at 4°C.  Then, 100 µl FM was 
added and the plate centrifuged as previous described. The supernatant was removed 
and the cells re-suspended well. Subsequently, 100 µl of Fix/Perm solution was added 
and the plate was incubated for 20 minutes at 4°C. The cells were washed twice by re-
suspending the cells in 200 µl Perm Wash (PW) and centrifuged at 240 g for 5 
minutes at 4°C. The compensation beads were prepared (described below) in parallel 
with the centrifugation. The supernatant was removed and the cells thoroughly re-
suspended.  50 µl/well fluorophore-conjugated rat-anti mouse antibodies (diluted 1/50 
in PW) were added and the plate was incubated for 30 minutes at 4°C. After the 
incubation, 150 µl PW was added and the plate was centrifuged at 380 g for 5 
minutes. Subsequently, the plate was washed twice with PW and centrifuged at 380 g 
for 5 minutes. The cells were re-suspended in 250 µl FM and analysed on the flow 
cytometer after compensating.  
Compensations 
The compensation beads were prepared by adding 3 drops of anti-rat + 3 drops of 
control beads to 1 mL of PW, then centrifuging at 1500 g for 2 minutes and re-
suspended in 350 µl PW. 50 µl beads were added to 6 different tubes (one for each 
fluorophore). Next, 1 µl of fluorophore-conjugated antibodies was added to each of 
the different compensation tubes and incubated for 30 minutes at 4°C (simultaneous 
to the cell incubation). After the incubation, 950 µl PW were added to each 
compensation tube. Then the compensation tubes were centrifuged at 1500 g for 2 
minutes and re-suspended in 250 µl FM before running the compensation tubes in 
flow cytometer. The samples and compensation tubes were stored protected from 
light for a maximum of 72 hours before flow cytometric analysis. 
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3.3 Statistical analysis 
To assess if the different groups had statistically significant differences, analysis were 
performed in Prism 5.0d for Mac OS X (GraphPad Software) using one-way ANOVA 
with Bonferroni adjustment for multiple-group comparison. P-values ≤ 0.05 were 
considered significant. For the HI-assay ± 95 % confidence interval was determined 
using Prism. 
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4 Results 
 
In this study we have analysed and compared the humoral and cellular immune 
responses in BALB/c mice to a virosomal influenza A/Vietnam/1194/2004 (H5N1) 
virus vaccine, administered sublingually (SL), intranasally (IN) and intramuscularly 
(IM) with (+) or without (-) the mucosal adjuvant c-di-GMP (see table 3.1). Sera, 
nasal wash (NW), saliva and spleens from the mice were used in different 
immunological assays to analyse the immune response after vaccination. The results 
are divided into humoral immune response and cellular immune responses, despite 
these arms of the immune system being closely related. 
 
4.1 Humoral Immune response 
Antibodies are the effectors of humoral immunity. The different antibody classes have 
different effector functions and can be found at distinct anatomic sites. We have 
focused on IgG, the class dominating the secondary immune response (see figure 1.3), 
and on IgA, which is important in mucosal immunity. The enzyme-linked 
immunosorbent assay (ELISA) was used to determine the concentrations of IgG, 
IgG1, IgG2a and IgA in the serum, IgA and IgG in the saliva and IgA in the NW. In 
addition, the local mucosal antibody response was evaluated by measuring the pIgR in 
the saliva and the NW. The functional antibody activity was assayed by determining 
the titre of the haemagglutination inhibition (HI) antibodies in the serum and the 
saliva. To enumerate the influenza-specific memory B cells in splenocytes the 
ELISPOT assay was used after in vitro polyclonal stimulation. In the following 
sections, the HI, ELISA and memory B-cell responses are presented.  
 
4.1.1 Haemagglutination inhibition (HI) assay 
To compare the different routes of administration and to assess the efficacy of the 
mucosal adjuvant c-di-GMP, the HI antibody titre in the sera and the saliva were 
measured at day 42 (euthanasia time-point). Sera were analyzed for antibodies against 
the homologous vaccine strain (A/Vietnam/1194/2004 (H5N1) NIBRG-14) (RG-14). 
HI titres ≥ 40 have been considered a surrogate correlate of protection for seasonal 
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influenza strains in man. Thus HI titres ≥ 40 were considered as protective titres, even 
though this assay has limitations when assessing pandemic vaccines in immunised 
mice.  
 
 
Figure 4.1: Haemagglutination inhibition titres in serum 3 weeks after 2nd dose 
BALB/c mice were vaccinated intramuscularly (IM), sublingually (SL) or intranasally (IN) 
with (+) or without (-) adjuvant. C-di-GMP in PBS was administered IN to controls (C). Sera 
were isolated from blood collected three weeks after the second vaccine dose, and assayed for 
haemagglutination inhibition titres against the vaccine strain (A/Vietnam/1194/2004 (H5N1) 
NIBRG-14) (RG-14). Error bars indicate geometric mean ± 95 % confidence interval. The 
dotted line represents the “protective HI titre” of 40. 
 
Sera isolated from cardiac blood were tested for HI-antibodies against the RG-14 
strain. The c-di-GMP adjuvanted virosomal H5N1 vaccine induced HI-titres ≥ 40 
against the vaccine strain (RG-14) by all administration routes (except from one non-
responder in the SL+ group) (figure 4.1). The IN+ group showed the highest 
geometric mean titre (GMT = 550) and all mice in this group had titres ≥ 320. The 
groups that were vaccinated with virosomes alone had generally lower GMTs than 
their respective adjuvanted groups but in the IM- group, all mice had protective HI-
titres ≥ 40. Control mice had no detectable HI titres. Comparing the different routes of 
administration, it was found that the IN+ group had the highest HI titres (GMT = 
550), followed by the IM+ (GMT = 350) and the SL+ (GMT = 115) groups.  
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Saliva samples from all mice in each group were pooled together and tested for HI 
antibodies against the vaccine strain (RG-14) (figure 4.2). None of the groups had HI 
GMT over the threshold correlated with protection (HI titres ≥40). The IN+ group had 
the highest HI GMT (GMT = 13.2) followed by the SL+ group (GMT = 9.2) and the 
IM+ group (GMT = 4.7). Among the non-adjuvanted groups, only the IM- group had 
a response (GMT = 3.2). No titres were seen in the non-adjuvanted mucosal groups 
and the control group. 
 
 
Figure 4.2: Haemagglutination inhibition titres in saliva detected three weeks after the 
second dose 
BALB/c mice were vaccinated intramuscularly (IM), sublingually (SL) or intranasally (IN) 
with (+) or without (-) adjuvant. C-di-GMP in PBS was administered IN to controls (C). 
Saliva samples were collected after i.p. injection with pilocarpine on the day of sacrifice, and 
the samples from all mice in each group were pooled to provide enough sample volume. The 
salivary HI assay was conducted three times and bars indicate geometric mean +95 % 
confidence interval.  
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4.1.2 ELISA 
The enzyme linked immunosorbent assay (ELISA) was used to determine the 
antibody concentrations in the serum and the nasal washes from all sampling days and 
the saliva from the day of euthanasia (see figure 3.1 for a detailed overview of 
sampling days).  
 
4.1.2.1 The mucosally administered vaccines induce a local antibody response 
A local immune response in the mucosa of the upper respiratory tract can prevent 
influenza infection. SIgA is the most important antibody class in the mucosal 
immunity, and have shown to elicit neutralising activity towards influenza [132]. 
SIgA has also been shown to be more cross reactive (i.e. cross clade activity) 
compared to other antibody classes [88]. Therefore, influenza-specific IgA antibodies 
were quantified in the nasal wash (NW) and the saliva samples. 
 
Saliva was collected from the mice three weeks after the second dose of vaccine (day 
42) and the concentrations of influenza (RG-14) specific IgG and IgA antibodies were 
determined (figure 4.3). IgG antibodies were detected in all administration groups 
except the control group, and the IN+ group had the highest IgG concentration (mean 
= 260 ng/mL). However, it was not statistically significantly higher than that found in 
the other adjuvanted groups. Only the IN+ group showed significantly higher (p ≤ 
0.05) levels of IgG compared to its respective non-adjuvanted group. IgA was found 
in much higher concentrations than IgG in the SL and IN groups (mean = 8300 ng/mL 
for the SL+ group and 11700 ng/mL for the IN+ group), whilst in the IM groups IgA 
was only detected at very low levels (mean = 8 ng/mL for the IM+ group). Both the 
IN+ and SL+ groups had significantly (p ≤ 0.05) higher levels of IgA than all the non-
adjuvanted groups, but no significant differences in IgA concentration were found 
between the adjuvanted mucosal groups.  
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Figure 4.3: Concentration of IgG and IgA in saliva samples three weeks after second 
vaccine dose 
BALB/c mice received two doses of virosomal influenza A/Vietnam/1194/2004 (H5N1) 
NIBRG-14 vaccine intramuscularly (IM), sublingually (SL) or intranasally (IN) with (+) or 
without (-) adjuvant. C-di-GMP in PBS was administered IN to controls (C). Saliva was 
collected from the mice after i.p. injection of pilocarpine, and analysed for IgG and IgA to 
investigate the local immune response. Each column represents the mean IgA concentration 
from six mice; error bars show the standard deviation. (*) indicates statistical significant 
differences between the groups (one-way ANOVA with Bonferroni correction, p ≤ 0.01).  
 
Nasal wash (NW) samples were collected by flushing 350 µl PBS/BSA (0.05%) 
through the mouth and nose of the mice (figure 3.5) and the samples were analysed 
for influenza-specific IgA antibodies (figure 4.4). After the first dose, IgA was only 
detected in the mucosally vaccinated groups and three weeks after the first dose there 
was no significant difference between SL+ and IN+. After the second dose, a higher 
immune response was elicited and both SL and IN administration induced high 
concentrations of IgA in the nasal cavity (up to 1200 ng/mL for the SL+ group and 
2800 ng/mL for the IN+ group). No IgA antibodies were detected in NW samples 
from control mice at any time point. The IN+ group had significantly higher (p ≤ 0.0) 
IgA concentrations than all other groups after the second dose. No IgA was detected 
in mice only receiving c-di-GMP. After the second dose, the intramuscular also group 
had low concentrations of IgA antibodies in the nasal cavity but surprisingly, higher 
concentrations were found in the non-adjuvanted than the adjuvanted group.  
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Figure 4.4: Concentration of influenza specific IgA in the nasal wash samples after 
vaccination 
BALB/c mice received two doses of virosomal influenza A/Vietnam/1194/2004 (H5N1) 
NIBRG-14 vaccine intramuscularly (IM), sublingually (SL) or intranasally (IN) with (+) or 
without (-) adjuvant. C-di-GMP in PBS was administered IN to controls (C). Nasal washes 
from all sampling days were analysed for influenza-specific IgA by the ELISA. Each column 
represents the mean IgA concentration from six mice; error bars show the standard deviation. 
(*) indicates statistical significant differences between the groups (one-way ANOVA with 
Bonferroni correction, *p ≤ 0.001). 
 
 
pIgR is also called the secretory component, and can reflect the amount of locally 
secreted IgA (SIgA). The pIgR was detected using an ELISA in the saliva and NW 
samples (figure 4.5 and 4.6). Since the IgA response in NW was higher after the 
second dose, only samples from two and three weeks after the second dose was tested 
for pIgR. The OD-values of pIgR were generally lower than the total IgA, but there is 
a clear association between the OD-values detected for IgA and pIgR both in NW and 
saliva samples, when we consider each mouse. The saliva samples had the highest 
amount of both total IgA and pIgR as compared to NW.   
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Figure 4.5: Influenza-specific IgA and pIgR in nasal wash samples 
BALB/c mice received two doses of virosomal influenza A/Vietnam/1194/2004 (H5N1) 
NIBRG-14 vaccine intramuscularly (IM), sublingually (SL) or intranasally (IN) with (+) or 
without (-) adjuvant. C-di-GMP in PBS was administered IN to controls (C). Nasal washes 
from mice sampled two weeks (2w2d) and three weeks (3w2d) after second dose were 
analysed for influenza-specific IgA and pIgR using ELISA. Total influenza-specific IgA 
concentrations and pIgR detected in NW collected from mice in the IN+ and SL+ group, two 
and three weeks after the second dose. Samples were diluted 1/50, and absorbance read at 492 
nm.  
 
0
1000
2000
3000
In
flu
en
za
-s
pe
cifi
c I
gA
 
co
nc
en
tra
tio
n 
(n
g/
m
l)
0 1 2 3 4 5 6
0.02
0.03
0.06
0.12
0.25
0.50
1.00
2.00
4.00
Mouse
Ab
so
rb
an
ce
 a
t 4
92
nm
 
(lo
g2
 s
ca
le
)
0
1000
2000
3000
IN+
SL+
0 1 2 3 4 5 6
0.02
0.03
0.06
0.12
0.25
0.50
1.00
2.00
4.00
Mouse
SL+ (Total IgA)
SL+ (pIgR)
IN+ (Total IgA)
IN+ (pIgR)
2w2d 3w2d
  4. Results 
 
 65 
 
Figure 4.6: Influenza-specific IgA and pIgR in saliva samples 
BALB/c mice received two doses of virosomal influenza A/Vietnam/1194/2004 (H5N1) 
NIBRG-14 vaccine intramuscularly (IM), sublingually (SL) or intranasally (IN) with (+) or 
without (-) adjuvant. C-di-GMP in PBS was administered IN to controls (C). Total influenza-
specific IgA concentrations and pIgR detected in saliva collected from mice in the IN+ and 
SL+ group, three weeks after the second dose. Samples were diluted 1/500, and absorbance 
read at 492 nm. Each data point represents each individual mouse in the IN+ and SL+ groups. 
 
Overall, both SL and IN administration elicited high IgA concentrations at the portal 
of entry for influenza virus, and large amounts of SIgA were secreted in saliva. 
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4.1.2.2 High concentrations of influenza-specific antibodies were detected in the 
serum 
To measure the systemic humoral immune response, the concentration of IgA and IgG 
were measured in the serum isolated from peripheral and cardiac blood.  
 
The concentrations of serum IgA were measured in samples taken at all time points 
(figure 4.7). The highest concentrations of IgA three weeks after the first dose (3w1d) 
were detected in the SL+ and IN+ groups. After the second dose, the IgA 
concentrations increased in all groups and the highest concentration was measured 
two weeks after second dose (2w2d) (mean = 30 µg/mL in the IN+ group). Three 
weeks after second dose (3w2d) the concentrations had decreased in all the vaccine 
groups. The IgA concentration in the IN + group were significantly higher (p ≤ 0.05) 
than in the IN- group throughout the study. Likewise, a significantly higher (p ≤ 0.05) 
IgA concentration was found in the SL+ as compared to the SL- group two weeks 
after the second dose. When comparing the mucosal administration routes, no 
significant differences were found, but both the IN+ and SL+ groups had significantly 
higher IgA concentrations in the serum that the IM+ group at two weeks after second 
dose (p ≤ 0.001). Control mice had no detected IgA in the serum at any time point. 
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Figure 4.7: Concentration of influenza-specific IgA in the serum samples after 1st and 
2nd immunisation 
BALB/c mice received two doses of virosomal influenza A/Vietnam/1194/2004 (H5N1) 
NIBRG-14 vaccine intramuscularly (IM), sublingually (SL) or intranasally (IN) with (+) or 
without (-) adjuvant. C-di-GMP in PBS was administered IN to controls (C). Sera were 
separated from blood collected at day 7 and 21 after the first vaccine dose, and day 14 and 21 
after the second vaccine dose, and tested for influenza-specific IgA antibodies. Each column 
represents the mean IgA concentration from six mice; error bars indicate the standard 
deviation. (*) and (**) indicate statistical significant differences between the groups (one-way 
ANOVA with Bonferroni correction, *p ≤ 0.05 **p ≤ 0.001).  
 
IgG is the most abundant antibody in the serum and most tissues, and serves many 
important functions such as opsonisation and neutralisation of antigens, activation of 
complement (the classical pathway) and antibody-dependent cell-mediated 
cytotoxicity (ADCC). High concentrations of influenza-specific antibodies were 
found, especially after the second dose (up to 3500 µg/mL in the IN+ group) (figure 
4.8). After the first dose, the IM+ group had the highest IgG response with a mean 
concentration of 40 µg/mL, statistical significantly different from all other groups one 
week after the first dose, and from all groups except the SL+ and IN+ groups three 
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weeks after the first dose. However, after the second dose of vaccine the IN+ group 
showed the highest IgG response, being statistically significantly (p ≤ 0.001) higher 
than all other groups. Three weeks after the second dose, only the IN+ group had 
significantly higher IgG concentrations as compared to the non-adjuvanted group. SL 
administration did not show significant differences between the adjuvanted and the 
non-adjuvanted group. When considering the virosomes alone, IM administration 
induced the highest IgG concentrations, however, not significantly different from the 
other non-adjuvanted groups. IgG antibodies were not detected in control mice at any 
time point.  
 
Figure 4.8: Concentration of influenza-specific IgG in serum from all sampling days 
BALB/c mice received two doses of virosomal influenza A/Vietnam/1194/2004 (H5N1) 
NIBRG-14 vaccine intramuscularly (IM), sublingually (SL) or intranasally (IN) with (+) or 
without (-) adjuvant. C-di-GMP in PBS was administered IN to controls (C). Sera were 
separated from blood collected at day 7 (1w1d), 21 (3w1d), 35 (2w2d) and 42 (3w2d), and 
tested for influenza-specific IgG antibodies. Each column represents the mean IgG 
concentration from six mice; error bars indicate the standard deviation. (*) and (**) indicates 
statistical significant differences between the groups (one-way ANOVA with Bonferroni 
correction, *p≤0.01 **p≤0.001).  
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4.1.2.3 IgG1 and IgG2a subclass responses 
Sera collected two weeks after the second dose (2w2d), at the peak of the IgG 
response, were analysed for two IgG subclasses; IgG1 and IgG2a (figure 4.9 and table 
4.1). The IN+ group had the highest mean concentrations of both IgG1 (mean = 591 
µg/mL) and IgG2a (mean = 1651 µg/mL), giving an IgG2a/IgG1 ratio at 2.79. The 
other mucosal administered group with c-di-GMP, the SL+ group, had much lower 
concentrations than the IN+ group. However, the IgG2a/IgG1 ratio was still over 1 
(IgG2a/IgG1 = 1.63), indicating a balanced but slightly Th1 biased response. IM 
administration with the adjuvant had almost similar IgG1 concentrations (mean = 580 
µg/mL) as compared to the IN+ group, but the concentrations of IgG2a was much 
lower (mean = 251 µg/mL) giving an IgG2a/IgG1 ratio at 0.72. Administration of the 
non-adjuvanted virosomes induced an IgG2a/IgG1 ratio below one (IM- = 0.08; SL- = 
0.09; IN- = 0.09), indicating a Th2 skewed response. In contrast, when c-di-GMP was 
included, mucosal administration produced a Th1 polarised response, whilst IM 
administration showed a more balanced profile with a slightly Th2 polarisation.  
 
a)      b) 
  
Figure 4.9: The concentrations of IgG1 and IgG2a and the ratio (between them) after 
the second vaccination 
BALB/c mice received two doses of virosomal influenza A/Vietnam/1194/2004 (H5N1) 
NIBRG-14 vaccine intramuscularly (IM), intranasally (IN) or sublingually (SL) with (+) or 
without (-) adjuvant. Controls (C) were only given c-di-GMP in PBS IN. Sera from mice 
collected at two weeks after the second dose were tested for the IgG subclasses, IgG1 and 
IgG2a. A) Concentration (µg/mL) of IgG2a and IgG1 in sera. The bars show IgG1 and IgG2a 
concentration on top of each other, the whole bar indicates the total IgG concentrations. B) 
IgG2a/IgG1 ratios. Columns show the relationship between IgG2a and IgG1. Values above 1 
(dotted line) indicate a Th1 skewed immune response. 
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Table 4.1: The IgG2a/IgG1 ratio and the T helper cell response 
BALB/c mice received two doses of virosomal influenza A/Vietnam/1194/2004 (H5N1) 
NIBRG-14 vaccine intramuscularly (IM), intranasally (IN) or sublingually (SL) with (+) or 
without (-) adjuvant. Controls (C) were only given c-di-GMP in PBS IN. Sera from mice 
collected at two weeks after the second dose were tested for the IgG subclasses, IgG1 and 
IgG2a. The ratios between IgG2a and IgG1 were determined for each vaccination group; 
IgG2a/IgG1 <1 indicate a Th2 polarised response; IgG2a/IgG1 >1 indicate a Th1 polarised 
response.  
Group IgG2a/IgG1 Th1 or Th2 
Mock 0.00 - 
IM- 0.08 Th2 
IM+ 0.72 Th2 
SL- 0.09 Th2 
SL+ 1.63 Th1 
IN- 0.09 Th2 
IN+ 2.79 Th1 
 
 
4.1.3 Mucosal vaccination induces high percentages of influenza-specific 
IgG memory B cells  
After vaccination with an influenza vaccine, the induction of immunological memory 
is important for protection against future influenza epidemics and pandemics of the 
same or similar influenza subtypes. We therefore measured the influenza-specific 
memory B-cell response in lymphocytes isolated from the spleen after polyclonal 
differentiation and proliferation by mitogen stimulation (figure 4.10 and 4.11). The 
IN+ and SL+ groups had the highest number of spots indicating memory B-cells able 
to secrete IgG antibodies against the vaccine strain (A/Vietnam/1194/2004 (H5N1) 
NIBRG-14). The IN+ group showed significantly (p ≤ 0.05) higher percentages of 
influenza (RG-14) specific cells of total IgG positive cells (up to 6.5 %) compared to 
all the other groups. The controls and the SL- group had no detectable memory B 
cells specific for RG-14, and the IM+ group had only barely detectable numbers. As 
in the IgA NW ELISA, the IM- group had higher percentages of influenza (RG-14) 
specific cells of total IgG positive cells (up to 1 %) as compared to the IM+ group.  
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a) Plate overview 
 
 
 
b) Non-responder (SL+ mouse 5) c) Responder (SL+ mouse 4) 
     
     
 
Figure 4.10: ELISPOT plates after development 
Lymphocytes from spleens were isolated and stimulated with mitogens. a) To determine the 
amount of influenza-specific memory B-cells, non-stimulated controls (÷, column 3-4, 7-8, 
11-12) were subtracted from the stimulated wells (+, column 1-2, 5-6, 9-10). Row A and H 
contain only blank wells without coating and lymphocytes respectively. Rows B-D were 
coated with virosomal influenza A/Vietnam/1194/2004 (H5N1) NIBRG-14 vaccine and row 
E-G were coated with IgG capture antibody. The plate depicted represents IN+, mouse 4-6. b) 
Pictures of single wells from a non-responder in the SL+ group. The upper well was coated 
with RG-14 virosomes; the lower well was coated with IgG capture antibodies to measure the 
total IgG secreting cells. c) Pictures of single wells from a responder in the SL+ group. The 
upper well was coated with RG-14 virosomes to measure the influenza-specific IgG secreting 
cells, the lower well was coated with IgG capture antibodies to measure the total IgG 
secreting cells. 
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+ 
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Figure 4.11: Memory B cell ELISPOT (IgG secreting cells) 
BALB/c mice received two doses of virosomal influenza A/Vietnam/1194/2004 (H5N1) 
NIBRG-14 vaccine intramuscularly (IM), sublingually (SL) or intranasally (IN) with (+) or 
without (-) adjuvant. C-di-GMP in PBS was administered IN to controls (C). Influenza-
specific memory B cells in the spleen were detected by memory ELISPOT after polyclonal 
differentiation and proliferation by mitogens. ELISPOT results are shown as percent RG-14 
influenza-specific memory B-cells secreting IgG of total IgG secreting memory B-cells. (*) 
and (**) indicates statistical significant differences between the groups (one-way ANOVA 
with Bonferroni correction, *p≤0.01 **p≤0.0001). 
 
Overall, the humoral immune response was good in all three administration routes, 
but the IN+ group had the highest response after two doses with the virosomal 
vaccine. The SL+ group had also good responses, however, one mouse in the SL+ 
group (mouse 5) had lower responses than the other mice in the same group (table 
4.2). IM vaccination induced high systemic humoral immune responses, but the local 
IgA production was poor. The inclusion of c-di-GMP gave statistical significantly 
higher responses than the non-adjuvanted group in all humoral assays when 
considering the IN administration, and in saliva IgA and serum IgA when considering 
the SL administration.  
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Table 4.2: The humoral response in the SL+ group three weeks after the second dose 
BALB/c mice received two doses of virosomal influenza A/Vietnam/1194/2004 (H5N1) 
NIBRG-14 vaccine sublingually (SL) with c-di-GMP. The grey area (mouse number 5) is a 
non-responder/low-responder through all the different humoral assays. 
ELISA 
SL+ 
mouse 
 
Serum 
HI 
titre  
 
Serum 
IgG 
(µg/mL) 
Serum 
IgA 
(µg/mL) 
NW IgA 
(ng/mL) 
Saliva 
IgG 
(ng/mL) 
Saliva 
IgA 
(ng/mL) 
ELISPOT 
(% RG-14 
of Total 
IgG) 
1 80 796 27.2 438 442 17400 0.82 
2 480 740 10.7 118 79.7 11100 1.01 
3 160 137 2.53 62 8.2 4527 0 
4 320 678 4.44 168 355 3820 5.17 
5 5 7 0 6.8 24.5 1152 0.56 
6 40 296 9.97 201 40.0 12000 0.56 
 
 
 
4.2 Cellular Immune response 
T cells are central in controlling immune responses. Helper T lymphocytes (CD4+ T 
lymphocytes) stimulate both inflammation and antibody production, and also help to 
activate the cytotoxic T lymphocytes (CTL), which are important for destroying 
influenza infected cells.  
 
4.2.1 Cytokine profiles 
Cytokine profiles can reveal the Th polarisation of an immune response after 
vaccination. IL-2, INF-γ and TNF-α indicate a Th1 skewed response, IL4-, IL-5 and 
IL-10 indicate a Th2 skewed response and IL-17 indicates a Th17 response. To assess 
the cytokine profile of the different administration routes with or without c-di-GMP, 
splenocytes isolated three weeks after the second dose were stimulated in vitro with 
RG-14 virosomal influenza antigen for 72 hours. The concentrations of IL-2, IL-4, IL-
5, IL-10, IL-17, IFN-γ and TNF-α in the cell supernatants were determined in the 
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multiplex bead assay (figure 4.12). Non-stimulated cells were incubated with medium 
alone and used as negative controls.  
 
 
Figure 4.12: Bioplex results depicting cytokine production from in vitro activated 
lymphocytes.  
BALB/c mice received two doses of virosomal influenza A/Vietnam/1194/2004 (H5N1) 
NIBRG-14 vaccine intramuscularly (IM), intranasally (IN) or sublingually (SL) with (+) or 
without (-) adjuvant. C-di-GMP in PBS was administered IN to controls (C). Splenocytes 
were isolated three weeks after second dose and incubated for 72 hours with 2.5 µg/mL H5N1 
virosomal RG-14 before harvest of supernatant for analysis. The concentrations of cytokines 
in the negative controls were subtracted from the cytokine concentration of stimulated cells. 
Each column represents mean values from six mice (Except for the control group which is 
only for three mice) and error-bars indicate standard error of the mean. (*) indicates statistical 
significant differences between the groups (one-way ANOVA with Bonferroni correction, 
*p≤0.05). 
 
 
The IN+ group had the highest concentration of the Th1 cytokines IL-2 (mean = 195 
426 pg/mL) and TNF-α (mean = 66,3 pg/mL), both being significantly higher (p ≤ 
0.05) as compared all to the other vaccination groups. No IL-2 was detected in the 
control group and the non-adjuvanted IM and IN groups. The highest concentration of 
IFN-γ was found in the SL+ group (mean = 33 772 pg/mL), however no statistically 
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lymphocytes. Spleenocytes was isolated three weeks after second dose and 
incubated 72 hours with 2.5 µg/ml H5N1 virosomal RG-14 before analysis. 
Each row represents mean values from six mice (Except for the mock group 
which is only for three mice) and errorbars indicate standard error of the mean.
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significant differences were seen between the different routes of administration. The 
Th2 cytokines were found in lower concentrations than the Th1 cytokines in the 
mucosal vaccinated groups. The IM+ and IM- groups showed significantly higher (p 
≤ 0.05) concentrations of both IL-5 and IL-10 than observed in most of the other 
groups. However, IL-5 and IL-10 cytokines were also measured in the control group 
that only received c-di-GMP intranasally, whereas no other cytokines were detected 
the control mice. Together this indicates that mucosal vaccination with RG-14 
virosomes and c-di-GMP induces a Th1 skewed immune response (which also is 
consistent with the IgG2a and IgG1 concentrations found in the ELISA). 
 
The Th17 response was evaluated by measuring the IL-17 concentration (figure 4.12). 
Only the IN and SL vaccinated groups had a detectable IL-17 production, and the c-
di-GMP adjuvanted groups had the highest concentrations (the IN+ group mean = 
37412 pg/mL; the SL+ group mean = 31511 pg/mL). However, only the IN+ group 
had significantly higher concentrations as compared to the non-responding IM+ and 
IM- groups. 
 
4.2.1 The induction of multifunctional T cells after vaccination 
The ability of CD4+ T lymphocytes to produce two or more cytokines simultaneously 
(multifunctional T-cells) may play a role in the protection against influenza virus. We 
have assessed the ability of mouse splenocytes to produce IL-2, IFN-γ and TNF-α 
alone or in combination after stimulation with the virosomal H5N1 vaccine (RG-14). 
Lymphocytes were fixed and subsequently stained for the intracellular cytokines and 
measured using multiparametric flow cytometry (figure 4.13). All c-di-GMP 
adjuvanted groups produced all three cytokines, whereas no cytokine producing cells 
were detected in non-adjuvanted groups and the control group (results not shown). 
Overall, the IN+ group had the highest frequency of influenza-specific cytokine 
producing CD4+ T cells (figure 4.13b).  The fraction of triple producers, double 
producers and single producers are described in pie charts (figure 4.13a). The IM+ 
group had the largest fraction of triple producers; approximately 30 % of the CD4+ T 
cells produce all three cytokines. The SL+ group has the largest fraction of double 
producers and IN+ has the largest fraction of single producers of the three groups. The 
IN+ group still had a higher fraction of double producers as compared to single 
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producers. This however, does not reflect the frequency of cytokine producing T cells 
but the distribution of the single, double and triple producers from the total cytokine 
producing cells. When focusing on the frequency of influenza-specific CD4+ T cells, 
the IN+ group had the highest amount of triple producers (mean = 0.4 %) compared to 
IM+ and SL+, where the mean frequency was 0.2 % and 0.1 %, respectively. The IN+ 
group also had a high a frequency of cells producing two cytokines; average 3 % of 
CD4+ T cells produced both IL-2 and TNF-α. These two cytokines were also 
produced simultaneously by average 1.5 % of CD4+ T cells in the SL+ vaccination 
group with c-di-GMP. Further, the SL+ group had few or no cells producing IFN-γ 
and TNF-α or IFN-γ and IL-2 simultaneously. The single-cytokine producing cells 
produced mainly TNF-α and the highest frequencies of these cells were observed in 
the IN+ and SL+ groups. 
 
a) 
 
b) 
 
Figure 4.13: Multiparametric flow cytometry detection of intracellular cytokines 
Splenocytes isolated three weeks after second dose were stimulated with the virosomal 
vaccine (A/Vietnam/1194/2004 (H5N1) NIBRG-14) for 17 hours. After fixation and 
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intracellular staining for IFN-γ, TNF-γ and IL-2, the cytokines were detected by flow 
cytometry. a) Pie charts showing fractions of single producers, double producers and triple 
producers in the control group and the adjuvanted groups. b) The percentage of CD4+ T cells 
that have produced cytokines after stimulation with virosomal influenza vaccine. The non-
adjuvanted groups had no or little cytokine production (not shown). Error bars indicate 
standard deviation. (*) and (**) indicates statistical significant differences between the groups 
(one-way ANOVA with Bonferroni correction, *p≤0.05 **p≤0.01).  (IM+ = intramuscularly 
with adjuvant, IN+ = intranasally with adjuvant, SL+ sublingually with adjuvant.) 
 
All together, a cell-mediated immune response was induced after all three types of 
immunisation, however, the mucosal routes induced higher concentrations of Th1 and 
Th17 cytokines and higher frequencies of CD4+ T cells than the intramuscular route. 
As seen in the humoral assays, the IN+ group generally showed the highest response, 
followed by the SL+ group. 
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5 Discussion 
 
The first transmission of H5N1 (avian influenza) from birds to man was registered in 
Hong Kong in 1997 [133]. Subsequently, sporadic cases of H5N1 infection in man 
have occurred in Asia and other countries with a large poultry industry, and the 
mortality rate has been high (≥ 60 %) [19]. No effective transmission of H5N1 from 
man to man has yet been reported, but could occur if H5N1 re-assorts with another 
viral subtype [134], and H5N1 thus poses a substantial pandemic threat.  
 
The ideal pandemic influenza vaccine should be easy to administer, cheap and 
provide long-term and cross-reactive protection, both systemically and mucosally, 
after one vaccine dose. Mucosal vaccination fulfils many of these requirements, and is 
therefore an attractive approach. Since no needles are involved in mucosal 
vaccination, the public acceptance and compliance rate would increase, and vaccine 
induced herd immunity would be high. Needle-free vaccination is also beneficial for 
use in the developing countries where blood borne infections are prevalent. Intranasal 
administration of influenza vaccines has been investigated for some time, but the 
close localisation of the nose to the brain and the clear association between an 
intranasal inactivated influenza vaccine and Bell’s Palsy [90], requires investigation 
of new mucosal routes of administration. Sublingual administration is used for many 
drugs (e.g. nitro-glycerine and desensitisation therapy for different allergies [135]), 
but only one study has looked into the sublingual route for administration of influenza 
vaccines [91]. 
 
A problem with avian influenza vaccines in man is that they have low 
immunogenicity [136-138]. To overcome this issue, high antigen doses (up to 90 µg 
HA) or an effective adjuvant have been used. Two vaccine doses have also been 
necessary to induce antibody levels associated with protection. Virosomes are virus 
like particles lacking genetic material, and have been shown to be very immunogenic 
and elicit high levels of protective antibodies and induce activation of CD4+ and 
CD8+ T cells [81]. In addition, virosomes can be less reactogenic as compared to 
whole virus vaccines (reviewed in [86]). Virosomes are also promising for mucosal 
vaccination [139].  
5. Discussion 
   
 79 
 
In this study we have found that IN administration of the virosomal vaccine combined 
with c-di-GMP generally induced the highest humoral and cellular immune responses. 
However, SL administration of the c-di-GMP adjuvanted vaccine elicited a mucosal 
immune response and can thus provide an alternative to the intranasal route. The only 
previous study on SL administration of influenza vaccines also depicted a great 
potential of the SL route [91].  
 
5.1 Induction of humoral immunity 
 
5.1.1 Haemagglutination inhibition titres induced after vaccination 
Antibodies can neutralize influenza virus and thus prevent infection [140]. Induction 
of antibodies in the sera and locally in the respiratory tract is one of the main goals 
after vaccination against influenza. However, in the requirements set by the European 
Medicines Agency for licensing of seasonal influenza vaccines in man, the only 
surrogate correlate of protection are related to serum antibody responses (e.g. HI titres 
≥40) [58]. Even though this threshold may not be applicable for pandemic strains like 
avian influenza, it is recommended that vaccines against these strains should be able 
to meet the same criteria as seasonal vaccines. HI titres ≥ 40 are therefore used as 
indicative of sero-protection in this study (in both the serum assay and the saliva 
assay).  
 
We found that all c-di-GMP adjuvanted groups had serum HI GMT ≥40 after two 
vaccine doses. IN vaccination with adjuvant gave the highest GMT as compared to 
both SL and IM vaccination with adjuvant (figure 4.1). This elevated immune 
response as compared to IM vaccination is consistent with previous work conducted 
by our group using c-di-GMP in combination with a subunit H5N1 or a plant 
produced H5 vaccine [141] and (unpublished data). In another study, where a 
different adjuvant (Matrix-M) but the same influenza virosomal vaccine was used, IM 
vaccination induced higher HI-titres than IN vaccination [123] illustrating the 
different functions of the two adjuvants. In our study, IN administration with adjuvant 
was the only adjuvanted group showing substantially higher serum HI GMT as 
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compared to the non-adjuvanted group. Among the adjuvanted groups, SL 
administration showed the lowest serum HI GMT, although this may have been 
influenced by one mouse in the SL+ group, which had no response in the assay. This 
mouse also responded poorly in many of the other assays and this was most likely due 
to difficulties in the SL vaccination in this mouse (see table 4.2). When considering 
the virosomes alone, only IM immunisation induced serum HI titres ≥ 40. This 
emphasises the need for an adjuvant when the vaccine is administered mucosally. 
 
When we tested the pooled saliva samples from each group for HI antibodies (figure 
4.2), the IN+ group showed the highest response, followed by the SL+ and IM+ 
groups. No groups had HI titres ≥40, which is the titre surrogate correlate of 
protection for HI-antibodies in human sera [59]. But no surrogate correlate of 
protection is based on HI titres in saliva; hence the salivary HI titres could be 
sufficient for protection. SIgA antibodies have shown the ability to neutralise virus 
[132], thus the HI antibodies in the saliva are likely to have local origin. However, the 
fact that both IM vaccination groups induced HI-antibodies in saliva, indicates an 
association with salivary IgG antibodies, which have been shown to have the ability 
to transudate from the serum to the upper respiratory tract [142].  The fact that we 
pooled the samples made the assay sensitive to outliers. From table 4.2, we can se a 
great variability in the SL+ group, which could have affected our results. However, 
the saliva HI GMTs correspond to the serological assays we conducted, hence the 
overall result is not much affected by the pooling.  
 
 
5.1.2 Intranasal and sublingual vaccination induce local IgA responses in 
the nasal wash and saliva 
IgA antibodies are the dominant antibody of the mucosal immune system, and are 
locally secreted as dimers and polymers (pIgA) joined together by a J-chain and 
secreted together with the soluble part of the polymeric Ig receptor (pIgR) [143]. 
Secretory IgA (SIgA) can neutralise influenza virus at the portal of entry, before the 
virus is able to establish an infection [132]. In addition, when the pIgA is trancytosed 
across the epithelium, also intracellular viruses can be neutralised [143]. SIgA has 
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also shown to be more cross-reactive than IgG, and can thus have neutralising activity 
against drifted influenza strains [88, 143]. 
 
In this study, one vaccine dose elicited only detectable IgA antibodies in the nasal 
wash samples from the mucosally immunised groups (figure 4.4), in agreement with 
previous findings using an IN adjuvanted vaccine [123, 141]. The secondary response 
after IN vaccination was much stronger than after SL vaccination when c-di-GMP 
was included, and the IN+ group showed significantly higher concentrations of IgA in 
the nasal wash as compared to the SL+ group. In contrast, the non-adjuvanted 
mucosal groups had similar IgA concentrations. Surprisingly, for the IM administered 
vaccines, the non-adjuvanted group showed a low response after the second dose, 
whilst the group that received virosomal vaccine with c-di-GMP IM had only barely 
detectable levels. However, the levels of local IgA in the upper respiratory tract after 
IM vaccination were much lower than in the to SL and IN groups, and would 
probably not have protected the mice from infection [144].  
 
In a murine study of intranasal vaccination with seasonal H1N1 and subsequent 
challenge with the same virus, an influenza-specific IgA concentration of 15 ng/mL 
found in the nasal wash correlated with no or reduced viral replication in the nasal 
cavity [144]. If we apply this concentration to our results, most of the mice in the 
mucosally administered groups would be protected from severe illness. But due to 
possible differences in assay protocols and since we use a different antigen and 
adjuvant, it is difficult to compare these studies. Therefore the next step would be to 
perform a highly pathogenic avian H5N1 challenge study in mice to assess the 
correlation between SIgA and protection.  
 
The concentrations of influenza-specific IgG and IgA were also measured in saliva 
(figure 4.3). IgA was only found in the groups receiving mucosally administered 
vaccine. A study in monkeys, which investigated the protective efficacy of an 
intranasal whole virus vaccine (NIBRG-14) combined with Ampligen® adjuvant, 
showed that high levels of IgA in the saliva correlated with low viral titres in the nose 
and throat and protection from pneumonia after highly pathogenic virus challenge 
[145]. Differences in the ELISA make it difficult to compare Ichinohe et al. with our 
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study; however, it shows the importance of IgA in saliva. We also measured the 
salivary IgG concentrations, and not surprisingly, much lower IgG concentrations 
were found in saliva as compared to serum IgG at the same time-point. No significant 
differences were found between the adjuvanted groups, whilst only the IN vaccination 
route showed a statistically significant difference between the adjuvanted and the non-
adjuvanted group. The concentration of salivary IgG (figure 4.3) correlates with the 
salivary HI GMT (figure 4.2); the mucosal adjuvanted groups had the highest 
response in both assays, whilst the IM- group had the highest response of the non-
adjuvanted groups.  
 
There were no statistically significant differences in salivary IgA concentrations 
between the SL+ and IN+ group, whereas significantly higher NW IgA was found in 
the IN+ group than in the SL+ animals. The reason for this could be an increased IgA 
response in the nose after IN administration of the vaccine, which we do not see after 
SL administration.  
 
The amount of influenza-specific pIgR was measured in nasal wash and saliva 
samples from all mice to identify the amount of locally secreted IgA (SIgA). Only the 
SL+ and IN+ group had detectable levels at the dilution used in the assay (figure 4.5 
and 4.6). The relationship between IgA and pIgR reflected the levels of SIgA as has 
been reported previously [146]. Compared to total IgA, SIgA was detected at lower 
OD-values in all samples, indicating that not all IgA antibodies found in the upper 
respiratory tract are actively transported into the lumen by pIgR. The remaining IgA 
may have been serum derived monomeric IgA or polymeric IgA only connected with 
the J chain, which had entered the upper respiratory tract mucosa [147]. The gap 
between IgA and pIgR could also be due to different sensitivity in the assays. 
Nonetheless, the results clearly show that the c-di-GMP adjuvanted vaccine induced 
influenza-specific SIgA antibodies both when administered intranasally and 
sublingually.  
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5.1.3 Intranasal vaccination induce systemic IgG and IgA responses 
The induction of systemic antibodies are important to eliminate influenza virus that 
have breached the barriers of the innate immune system and escaped the SIgA 
antibodies in the mucosa of the respiratory tract.  
 
IgG antibodies have a superior specificity and serve many important functions in 
protection against influenza. High levels of serum IgG are associated with a reduction 
of viral shedding [148] and can cross the alveolar walls of the lungs, and thereby 
protect against viral pneumonia [149]. In this study, the IM+ group had significantly 
higher IgG concentrations than all the other groups after the first vaccine dose. 
However, after the second dose, we found significantly higher concentrations of IgG 
in the IN+ group as compared to the IM+ and SL+ groups (figure 4.8). However, no 
significant difference was found between SL and IM vaccination when adjuvanted 
with c-di-GMP. In contrast, previous studies have shown that IM administration of a 
virosomal influenza vaccine with Matrix-M adjuvant, and IM administration of a 
whole influenza virus vaccine, induced higher IgG concentrations in sera than IN 
administration [123] and (unpublished data). When we considered the virosomes 
alone, the IM- group showed the highest IgG concentration, consistent with what we 
found in the serum HI assay. Again, the need for a good mucosal adjuvant is 
highlighted. A previous study in mice showed that an IgG concentration of 38 µg/mL 
in the serum was associated with undetectable levels of virus in mouse lung washes 
after viral challenge with seasonal H1N1 [144]. Interestingly, in our study the mean 
IgG concentration in serum was higher in all groups after two vaccine doses (except 
the IN- group), than the concentration associated with undetectable levels of virus in 
the lungs. But as previously discussed, comparison of ELISA results between 
different labs are difficult because of the different protocols used.  
 
The IN+ group had significantly higher serum IgA concentrations after one vaccine 
dose as compared to all other groups, except the SL+ group (figure 4.7). Two weeks 
after the second dose the SL+ group also had IgA concentrations significantly higher 
than the concentrations found in all other groups, except the IN+ group. The peak IgA 
response was, in all groups, found two weeks after the second dose, and a small 
decrease in IgA concentration was observed from two weeks to three weeks after the 
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second dose. The decreasing concentration is possibly caused by declining numbers 
of IgA producing short-lived plasma cells or the short half-life of IgA antibodies in 
serum. Due to the high levels of serum IgA in the mucosally vaccinated groups 
compared to the intramuscular vaccinated groups, it is possible that some of these 
antibodies have a mucosal origin. 
 
5.1.4 Memory B cell ELISPOT 
A population of B cells activated by antigen are able to survive for a longer period of 
time and are called memory B cells. Memory B cells can induce rapid antibody 
responses after subsequent encounter with the same antigen, and are therefore an 
important part of the immune response after vaccination. In addition, memory B cells 
can be an important source of cross-reactive antibodies [150, 151]. The enumeration 
of memory B cells may also give an indication of the longevity and magnitude of the 
vaccine response, since they are formed in germinal centres where long-loved plasma 
cells also are formed. After differentiation into memory B-cells, some of these cells 
stay in the germinal centre of the lymph nodes, whilst others re-circulate between the 
spleen and lymph nodes [152].  
 
The SL+ and IN+ vaccines induced differentiation into memory B cells (figure 4.11), 
again illustrating the efficiency of c-di-GMP as a mucosal adjuvant. However, only 
IN vaccination showed significantly higher numbers of influenza-specific IgG 
secreting memory B cells as compared to the other vaccination groups. The IM- and 
the IN- group also had a memory B cell response, albeit low, whilst no response was 
observed in the IM+ group. Interestingly, we saw a higher response in the non-
adjuvanted IM group than in the adjuvanted IM group, consistent with the results seen 
in the NW IgA ELISA (figure 4.4). It was also surprising that IM vaccination induced 
such low numbers of RG-14 specific IgG secreting memory B cells, since the IgG 
serum concentrations in the IM+ group was similar to that of the SL+ group. 
However, it is unclear if the numbers of memory B cells correlate with antibody 
concentrations in sera [131], and other findings suggest that memory B cells and ASC 
plasma cells are independent of each other [153]. To assess the amount of ASC after 
vaccination, we should have used the direct ELISPOT assay.  
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5.2 Induction of cellular immunity 
T cells are essential for the prevention and recovery from influenza virus infection 
[140], however, there are no international standards for measurement of cell-mediated 
immune (CMI) responses after influenza vaccination and no correlate of protection 
based on CMI has been established.  
 
5.2.1  Cytokine profiles and IgG subclasses 
Vaccines should preferably activate both the Th1 (IgG2a, IL-2, IFN-γ and TNF-α) 
and Th2 subsets (IgG1, IL-4, IL-5, and IL-10) of T helper cells, since both are 
important for elimination of influenza virus from the host [154, 155]. We found serum 
IgG2a domination in both the SL+ and IN+ groups, which indicates a Th1 polarised 
response (figure 4.9). This is supported by the high concentrations of the Th1 
cytokines IL-2 and IFN-γ in the supernatants of influenza stimulated splenocytes 
(figure 4.12). However, the IN+ group had a stronger polarisation towards Th1 as 
compared to the SL+ group. This is consistent with other studies carried out using 
intranasal administration with adjuvants where a Th1 skewed response is elicited 
[156], whilst sublingual immunisation gives a more balanced Th1/Th2 response [92]. 
In contrast, the IM+ group produced similar amounts of IgG1 and IgG2a, and 
cytokines from both the Th1 and Th2 subsets were found upon in vitro stimulation of 
splenocytes, depicting a balanced Th1/Th2 response. Another study conducted in our 
group, where a different adjuvant was used, found a balanced Th response in mice 
both when vaccinated intranasally and intramuscularly [123]. All the non-adjuvanted 
groups produced an excess of IgG1 as compared to IgG2a (figure 4.9). In addition the 
non-adjuvanted groups produced lower Th1 responses, but similar Th2 cytokine 
levels as compared to the SL+ and IN+ groups. Thus, the virosomes alone induced a 
Th2 skewed response whilst inclusion of c-di-GMP induced a more balanced (IM) or 
Th1 biased response (SL and IN). Both Th1 cytokines and IgG2a antibodies are 
important mediators in promoting antibody-dependant cell-mediated cytotoxicity 
(ADCC) [157, 158], suggesting that SL and IN vaccination combined with c-di-GMP 
would elicit greater protection and be able to eradicate virus-infected cells more 
effectively than IM vaccination and all the non-adjuvanted vaccine groups.  
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IL-10 is considered a Th2 cytokine, and inhibits Th1 differentiated cells. IL-10 is also 
associated with enhanced IgA class-switch, thus increasing the production of IgA 
(reviewed in [41]). In spite of this, we found similar concentrations of IL-10 in all 
groups, except for the IN+ group where no IL-10 was detected. This can perhaps be 
explained by the substantial Th1 polarisation of the IN+ group. However, also the 
control group (which received only c-di-GMP alone) had detectable levels of IL-10, 
indicating no association between IL-10 and influenza-specific IgA production in this 
study. Another Th2 cytokine associated with IgA class-switch is IL-4 (reviewed in 
[41]). Similar to IL-10, no IL-4 was detected in the SL+ and IN+ groups despite the 
high concentrations of IgA found both locally and systemically in these groups. In 
addition, TGF-β is a cytokine that induces IgA class-switch [159, 160], and it would 
have been interesting to measure this cytokine in the supernatant of in vitro stimulated 
lymphocytes. This could have explained the high levels of IgA in the mucosally 
immunised mice. Also the concentration of the respective cytokines can be different 
between local compartment lymphoid tissues and the spleen, therefore sampling of 
cervical lymph nodes would have given us a better picture of the local CMI. Other 
explanations for the weak association between high IgA concentration and IgA 
inducing cytokines could be due to incorrect stimulation, lack of sensitivity of the 
assay and/or sampling time point.  
 
Th17 is a newly discovered subset of Th cells and has been associated with 
inflammation and protection against extracellular pathogens and helminths [161]. 
Recent findings have shown that a Th17 cytokine (IL-17) is also important in the 
immune response towards pathogens at mucosal sites. IL-17 has been detected in 
murine lungs after infection with influenza [162]. In our study, high levels of IL-17 
were found in the mucosally vaccinated mice, whereas no IL-17 was detected in mice 
receiving the vaccine intramuscularly (figure 4.12). Similarly, a previous study has 
found high levels of IL-17 after intranasal vaccination [163]. The importance of Th17 
cells in influenza infections is debatable, but a challenge study using influenza PR8 
(H1N1) found an improved survival rate in mice with increased Th17 cytokine 
concentration in the lungs [164]. If we extrapolate this to our results, the IN and SL 
vaccinated mice would be protected against influenza associated illness and death. In 
contrast, in a previously study of Matrix-M adjuvanted virosomal vaccine conducted 
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in our group, the IL-17 production from influenza stimulated splenocytes did not 
correlate with the protection against lethal challenge with influenza [124]. 
Nonetheless, these results are the first to show that SL administration of influenza 
vaccines can induce a Th17 response. 
 
5.2.2 Multifunctional T cells 
Induction of CD4+ T cells producing more than one cytokine simultaneously has been 
shown to correlate with the protection against infections other than influenza [36, 165, 
166]. In addition, multifunctional T cells have been shown to produce higher levels of 
cytokines as compared to single cytokine producing T cells [35].  
 
In this study, we have shown that mucosal vaccination in combination with c-di-GMP 
induces high frequencies of influenza-specific multifunctional T cells (figure 4.13). 
The IN+ group had the highest frequency of influenza-specific CD4+ T cells 
producing three cytokines (TNF-α, IFN-γ and IL-2) and any combination of two 
cytokines. Among the double-producers, the TNF-α+IL-2+ cells showed the highest 
frequencies in both the adjuvanted mucosal groups (IN+ and SL+) with adjuvant. The 
same double-producers have been found in high frequencies after influenza 
vaccination studies in our group, using a different adjuvant and the same virosomal 
antigen [123], and using the same c-di-GMP adjuvant but a different H5 antigen 
[141]. In contrast, other studies investigating vaccines against Leischmania Major and 
Mycobacterium Tuberculosis, found a double cytokine producer response dominated 
by TNF-α+IFN-γ+ cells [36, 165, 166]. This can indicate that influenza vaccination 
mainly induces TNF-α+IL-2+ cells; however, also TNF-α+IFN-γ+ cells were found in 
the IN+ and the IM+ groups (figure 4.12b). Among the single cytokine producing 
cells, the TNF-α+ cells were most abundant in all groups. IL-2+ cells had lower 
frequencies, and IFN-γ+ cells were only barely detectable. Thus, IFN-γ is mainly 
produced together with other cytokines. IFN-γ, TNF-α and IL-4 have been shown to 
increase the pIgR gene expression [167-169], which could explain the higher 
concentrations of IgA and pIgR in the nasal washes and the saliva in the IN+ and SL+ 
groups (figure 4.5). The frequencies of antigen-specific cytokine producing (triple, 
double and single producers) cells in our study are higher than previously reported 
[36, 165, 166], indicating that c-di-GMP is an effective mucosal adjuvant.  
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We found that the SL+ and IN+ groups had higher frequencies of CD4+ T cells 
producing cytokines than the IM+ group, indicating that mucosal vaccination with c-
di-GMP is highly effective at inducing CD4+ T cell responses. Nonetheless, as 
illustrated in the pie charts (figure 4.12a) despite the lower frequencies, a higher 
proportion of cells in the IM+ group than the mucosal groups produced all three 
measured cytokines simultaneously, hence higher levels of cytokines could have been 
produced from these cells [35].  
 
 
5.3 Limitations of the study  
In this study we have assessed the immune response after vaccination with an H5N1 
virosomal vaccine. There is, however, no established surrogate correlate of protection 
after vaccination against avian H5N1 [59]. The next step in evaluating the vaccine is 
to assess the protective efficacy, and evaluate and correlate the immune response to 
protection from illness and death. Anyhow, we have previously reports that two IM 
doses of 1 µg HA of the virosomal vaccine alone can protect mice against HPAI 
[124]. In the present study, all groups receiving the c-di-GMP adjuvanted vaccine had 
higher immune responses than the IM- group, suggesting that these groups would also 
be protected from HPAI challenge. 
 
When vaccinating the mice intranasally and sublingually, it is important that the 
whole vaccine volume is absorbed in the nasal cavity and under the tongue, 
respectively. If some of the vaccine is swallowed, the immune response may be 
drastically decreased due to acidic and enzymatic degradation of the antigen and/or 
adjuvant in the stomach. Should any antigen reach the mucosa in the gastrointestinal 
tract intact, an immune response may be induced, but at the wrong immunological 
site. However, we used a small volume (7 µl), which previously has been reported to 
be retained in the sublingual mucosa [91], and by placing the mice in positions that 
should prevent them from swallowing the vaccine, we reduced this risk to a 
minimum. Similar problems apply to IN vaccination, however, protocols for IN 
vaccination have been optimised in our lab. 
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Overall, the IN+ group elicited the highest immune response in all immunological 
assays. The SL+ group showed a similar, but generally lower response. This may be 
due to difficulties in performing the SL vaccination. In addition, the antigen uptake 
under the tongue can be different from the antigen uptake in the nose, and the NALT 
has been shown a superior mucosal site to the other MALTs (reviewed in [39]). Also 
salivary enzymes, which not are present in the nasal cavity, could play a role in the 
reduced immunogenicity in SL as compared to IN administration of the c-di-GMP 
adjuvanted virosomal vaccine. 
 
 
The vaccination technique can also be one of the reasons for the variability between 
mice within one vaccine group, especially the SL groups (see table 4.2). The sampling 
(especially NW sampling) technique, e.g. spills or incorrect technique, could also 
explain some of the variability between the mice. Nutritional status and stress levels 
can have a huge impact on the immune status [170-172], hence the immune response 
after vaccination could be altered differently for an individual mouse, depending upon 
the stress level after transport and handling of the mice. Variability within the SL+ 
group can be one of the reasons for the lack of statistically significant differences 
between the SL+ and the SL- groups. Furthermore, this is the first sublingual study in 
our group; hence some of the protocols were not fully optimised. The present study 
will therefore form a pilot study for future development of assays and vaccination 
protocols.  
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5.4 Conclusions 
In this study, we were the first to evaluate the sublingual route for administration of 
an H5N1 virosomal influenza vaccine, and found further evidence that this route of 
administering influenza vaccines can be an attractive alternative to intranasal 
vaccination. In addition, we evaluated the c-di-GMP adjuvant, and found that, for all 
administration routes, the combination of c-di-GMP and the virosomal vaccine 
induced higher immune responses than the virosomes alone, thus illustrating the need 
for a good mucosal adjuvant. 
 
Both the mucosal c-di-GMP adjuvanted vaccination groups induced strong humoral 
(both systemic and local) and cellular immune responses, with a Th1 polarisation, and 
high frequencies of influenza specific multifunctional CD4+ T cells. The 
intramuscular route showed similar systemic antibody responses, but lower local 
antibody concentrations, as compared to the mucosal routes. In addition, the 
intramuscular route induced a Th2 polarisation irrespective of the inclusion of c-di-
GMP adjuvant. Interestingly, lower frequencies of influenza-specific multifunctional 
CD4+ T cells were found after intramuscular vaccination, than for the mucosal 
vaccination groups. All three administration routes induced serum HI GMT ≥40 when 
the virosomes were combined with c-di-GMP, thereby fulfilling the CHMP criteria 
for seasonal vaccines in man [58].  
 
 
5.5 Further research 
In this study, we have evaluated the humoral and cellular immune response after SL, 
IN and IM vaccination of an H5N1 virosomal vaccine with or without c-di-GMP in a 
murine model. To get a more detailed evaluation of the SL route, further studies 
characterising the immune response in more detail (e.g. microneutralisation assay, 
CD8+ T cell and NK cell assays and long-term immunity), and survival after lethal 
viral challenge, are needed. In addition, it would have been interesting to further 
investigate the local immune response, by isolating cells from the appropriate 
draining lymph nodes for each administration route and assess the cell-mediated 
immunity (e.g. in vitro activation, multifunctional T cells). 
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Cross-clade immunity is important for pandemic vaccines as the H5N1 are 
antigenically distinct in different geographical locations, thus further investigation of 
the cross-reactivity of the virosomal vaccine combined with c-di-GMP is necessary. 
We therefore suggest evaluation of cross-protection, both by assessing cross-reactive 
immune responses and by lethal viral challenge with heterologous influenza strains. 
 
In a pandemic situation, one of the possible challenges would be limited amount of 
antigen for vaccine production, and the antigen dose in each vaccine dose should be 
as low as possible. We used a low dose of antigen (2 µg HA) and previous studies in 
our group have shown that c-di-GMP had a dose sparing effect (unpublished data). 
We would suggest a dose-efficacy study using the virosomal antigen and c-di-GMP to 
further assess the dose sparing potential of this adjuvant.  
 
The eventual goal for all vaccines is to obtain marketing authorisation for human use. 
Today, no mucosal adjuvants are licensed, however, most mucosal vaccines require 
an effective adjuvant. C-di-GMP has in this study shown great potential as a mucosal 
adjuvant, and we therefore suggest further toxicity studies and further 
immunogenicity studies in larger animal models (ferrets and monkeys) to build a non-
clinical dossier.  
 
Further investigation of the SL route should also address formulation issues. Since the 
vaccine is to be administered in the mouth, organoleptic properties (e.g. taste, odour 
and colour) are important for compliance and should be thoroughly investigated. The 
viscosity and solubility of the formulated vaccine are also important, as the vaccine 
should stay under the tongue for as long as possible to increase absorption of antigen 
and adjuvant. Also, the formulation should (if formulated as a tablet) rapidly 
disintegrate when placed under the tongue. 
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